

FOIA MARKER

**This is not a textual record. This is used as an
administrative marker by the William J. Clinton
Presidential Library Staff.**

Collection/Record Group: Clinton Presidential Records
Subgroup/Office of Origin: National AIDS Policy Office
Series/Staff Member: Kristine Gebbie
Subseries:

OA/ID Number: 3767
FolderID:

Folder Title:
September Chron Files 1993 [3]

Stack:	Row:	Section:	Shelf:	Position:
S	66	5	3	3

Withdrawal/Redaction Sheet

Clinton Library

DOCUMENT NO. AND TYPE	SUBJECT/TITLE	DATE	RESTRICTION
001. letter	From: Kristine Gebbie; re: Diagnosis (1 page)	09/10/1993	b(6)
002. memo	George K. Degnon to Selected ASTHO [Association of State and Territorial Health Officials] Members; re: Diagnosis (1 page)	08/31/1993	b(6)
003. letter	From: Kristine Gebbie; re: Diagnosis [Duplicate of 001] (1 page)	09/10/1993	b(6)
004. memo	George K. Degnon to Selected ASTHO [Association of State and Territorial Health Officials] Members; re: Diagnosis [Duplicate of 002] (1 page)	08/31/1993	b(6)
005. letter	The Ervin's to Dear Friends; re: Diagnosis (1 page)	08/14/1993	b(6)
006. letter	To: John H. Gibbons; re: Grant (1 page)	08/26/1993	b(6)
007. letter	To: Kristine Gebbie; re: Physician/Educator (1 page)	08/14/1993	b(6)
008. resume	[Personally Identifiable Information] [Partial] (1 page)	08/03/1993	b(6)
009. letter	To: Kristine Gebbie; re: Congratulations on Appointment (5 pages)	08/30/1993	b(6)
010. envelope	To: Kristine Gebbie; [Personal] [Partial] (1 page)	08/30/1993	b(6)

COLLECTION:

Clinton Presidential Records
National AIDS Policy Office
Kristine Gebbie
OA/Box Number: 3767

FOLDER TITLE:

September Chron Files 1993 [3]

2018-0756-F

jp4790

RESTRICTION CODES

Presidential Records Act - [44 U.S.C. 2204(a)]

- P1 National Security Classified Information [(a)(1) of the PRA]
- P2 Relating to the appointment to Federal office [(a)(2) of the PRA]
- P3 Release would violate a Federal statute [(a)(3) of the PRA]
- P4 Release would disclose trade secrets or confidential commercial or financial information [(a)(4) of the PRA]
- P5 Release would disclose confidential advice between the President and his advisors, or between such advisors [(a)(5) of the PRA]
- P6 Release would constitute a clearly unwarranted invasion of personal privacy [(a)(6) of the PRA]

C. Closed in accordance with restrictions contained in donor's deed of gift.

PRM. Personal record misfile defined in accordance with 44 U.S.C. 2201(3).

RR. Document will be reviewed upon request.

Freedom of Information Act - [5 U.S.C. 552(b)]

- b(1) National security classified information [(b)(1) of the FOIA]
- b(2) Release would disclose internal personnel rules and practices of an agency [(b)(2) of the FOIA]
- b(3) Release would violate a Federal statute [(b)(3) of the FOIA]
- b(4) Release would disclose trade secrets or confidential or financial information [(b)(4) of the FOIA]
- b(6) Release would constitute a clearly unwarranted invasion of personal privacy [(b)(6) of the FOIA]
- b(7) Release would disclose information compiled for law enforcement purposes [(b)(7) of the FOIA]
- b(8) Release would disclose information concerning the regulation of financial institutions [(b)(8) of the FOIA]
- b(9) Release would disclose geological or geophysical information concerning wells [(b)(9) of the FOIA]

THE WHITE HOUSE
WASHINGTON

September 8, 1993

Mr. Richard D. Hofferber
911 North K Street #113
Tacoma, Washington 98403

Dear Mr. Hofferber:

Thank you for the information on the READY Program. You are correct that prevention of substance abuse is an essential part of our response to the HIV epidemic.

I will share the information on your program with the Centers for Disease Control and Prevention.

Sincerely,



Kristine M. Gebbie, RN, MN
National AIDS Policy Coordinator

sent to CDC on 9/9/93

7304

THE WHITE HOUSE
WASHINGTON

September 8, 1993

Mr. Richard D. Hofferber
911 North K Street #113
Tacoma, Washington 98403

Dear Mr. Hofferber:

Thank you for the information on the READY Program. You are correct that prevention of substance abuse is an essential part of our response to the HIV epidemic.

I will share the information on your program with the Centers for Disease Control and Prevention.

Sincerely,



Kristine M. Gebbie, RN, MN
National AIDS Policy Coordinator

THE WHITE HOUSE
WASHINGTON


September 8, 1993

Ms. Diane Ledbury
511 Stevens Court, N.W.
Renton, Washington 98055

Dear Ms. Ledbury:

Thanks for writing. I intend to use our best science to pursue HIV policy as a public health issue.

Sincerely,

A handwritten signature in dark ink, appearing to read "Kristine Gebbie". The signature is fluid and cursive, with a large initial "K" and a stylized "G".

Kristine M. Gebbie, RN, MN
National AIDS Policy Coordinator

THE WHITE HOUSE
WASHINGTON

September 8, 1993

Ms. Diane Ledbury
511 Stevens Court, N.W.
Renton, Washington 98055

Dear Ms. Ledbury:

Thanks for writing. I intend to use our best science to pursue HIV policy as a public health issue.

Sincerely,

Kristine M. Gebbie, RN, MN
National AIDS Policy Coordinator

Prepared by: APO: KMGebbie: gw: 9/2/93: 632-1090: b:\ledbury

FILE
COPY

OFFICE	SURNAME	DATE	OFFICE	SURNAME	DATE	OFFICE	SURNAME	DATE

It's disgusting the way
Congress has fiddled
away opportunities to
be effective on AIDS
because they're so "moral".

How moral is it to cause
vastly more cases than is
necessary.

I'll return to what I've
written before. AIDS is a
health not a moral issue
Suck it to 'em
Diana Ledbury

Panel: Rigorous AIDS campaign could cut new HIV cases in half

WASHINGTON (AP) - The government could cut the spread of the AIDS virus in half with a serious prevention campaign, the National AIDS Commission said Tuesday.

The commission, which goes out of business in about three weeks, took its last shots at the Bush administration and Congress, complaining that politics and ideology had interfered with an effective education effort to prevent AIDS.

"The many decisions that have limited the contributions of the behavioral and social sciences to fighting AIDS have resulted in more HIV infections than should have occurred," the report said. "Continuation of this situation is morally indefensible."

The Bush administration did have a public education campaign on AIDS, but it was repeatedly criticized for trying so hard to be inoffensive its message was lost. Public service advertisements, for example, did not mention the word "condom."

Congress also was blamed for substituting its own judgment for that of scientists in deciding how the government should spend its

research money. As a result marginal research sometimes gets money and worthy research gets cut off, the report said.

The commission blamed a lack of public sympathy for homosexual men and intravenous drug users, the chief victims of AIDS in the United States. The human immunodeficiency virus, which causes AIDS, is spread most often through sexual contact and needles or syringes shared by drug addicts.

"The specter of male homosexuality has repeatedly been used to circumscribe AIDS prevention efforts," the commission said. "The result has been the development of local community review panels . . . to avoid 'offensiveness.'"

The Centers for Disease Control and Prevention estimate there will be 40,000 to 80,000 new HIV infections in the United States over the next year, but that could be drastically cut if the government started an AIDS prevention initiative, the report said.

The AIDS Commission was established by Congress and began operation in 1989.

PHOTOCOPY
PRESERVATION

Thanks for writing.
I intend to use our best
science to pursue HIV policy
as a Ph. issue.
Sincerely

MRS EUGENE A LEDBURY
511 STEVENS COURT NW
RENTON WA 98055



Kristine Bekkie
AIDS Czar
1600 Penn. Ave
The White House
W.A. D.C. 20500

7300

THE WHITE HOUSE
WASHINGTON

September 8, 1993

Ms. Pamela J. Haylock, R.N., M.A.
Secretary, Board of Directors
Oncology Nursing Society
501 Holiday Drive
Pittsburgh, Pennsylvania 15220-2749

Dear Ms. Haylock:

Thank you for writing and for your offer of support.

I would be pleased to meet with representatives of ONS to discuss areas of mutual concern. If this would work out, please contact Ms. Retina Holmes at (202) 632-1090.

Sincerely,



Kristine M. Gebbie, RN, MN
National AIDS Policy Coordinator

THE WHITE HOUSE
WASHINGTON

September 7, 1993

Ms. Pamela J. Haylock, R.N., M.A.
Secretary, Board of Directors
Oncology Nursing Society
501 Holiday Drive
Pittsburgh, Pennsylvania 15220-2749

Dear Ms. Haylock:

Thank you for writing and for your offer of support.

I would be pleased to meet with representatives of ONSto discuss areas of mutual concern. If this would work out, please contact Ms. Retina Holmes at (202) 632-1090.

Sincerely,

Kristine M. Gebbie, RN, MN
National AIDS Policy Coordinator

Prepared by: APO: KMGebbie: gw: 9/6/93: 632-1090: b:\haylock

FILE
COPY

OFFICE SURNAME	DATE	OFFICE SURNAME	DATE	OFFICE SURNAME	DATE

THE WHITE HOUSE
WASHINGTON

Thank you for writing and
for your offer of
support.

I would be pleased to
meet with ~~my~~ representatives
of ONS to discuss
areas of mutual concern.
If this would work out,
please contact Peter Holm
at

Sincerely



ONCOLOGY NURSING SOCIETY

501 Holiday Drive
Pittsburgh, PA 15220-2749
412/921-7373
FAX# 412/921-6565

PAMELA J. HAYLOCK, RN, MA
Secretary

Home: 415/851-2881

Work and Fax: 415/851-5620



ONCOLOGY
NURSING
SOCIETY

501 Holiday Drive
Pittsburgh, PA 15220-2749
(412) 921-7373

August 19, 1993

Kristine M. Gebbie, MN, RN, FAAN
AIDS Policy Coordinator
Office of AIDS Coordination
The White House
1600 Pennsylvania Ave.
Washington, D.C., 20500

Dear Ms. Gebbie:

On behalf of the Board of Directors of the Oncology Nursing Society (ONS) and the general membership, I offer congratulations on your appointment as AIDS Policy Coordinator. We offer not only our congratulations -- your appointment is indeed a well-deserved honor. Your credentials and experience give us a great deal of confidence that you are up to the task before you. But we also offer our help. ONS members have been actively involved in responding to the multifaceted issues created by the human immunodeficiency virus since its appearance more than a decade ago. Indeed, oncology nurses were among the first to respond to the needs of people affected by this virus, and many continue to be on the front lines in this battle.

ONS stands ready and willing to serve as a resource: we offer technical and experiential skills, and our growing body of knowledge to you. We support members' efforts to address the present and future threat imposed by HIV and AIDS, and hope you will take advantage of the compassion and expertise we offer. We wish you the very best as you take on this important endeavor.

Respectfully,

Pamela J. Haylock, R.N., M.A.
Secretary, Board of Directors

cc: Pearl Moore
Board of Directors

THE WHITE HOUSE

WASHINGTON

September 9, 1993

Mr. Prospero R. Patlingrao
64 Carlock Street
Cebu City 6000
Philippines

Dear Mr. Patlingrao:

Thank you for your letter regarding your formula for AIDS treatment and desire to immigrate to the United States.

Enclosed is information on several research fellowship opportunities through the National Institutes of Health, Bethesda, Maryland that you may wish to contact. International training fellows must be nominated by their country of citizenship for these fellowships. The address of the nominating committee in The Philippines is:

Dr. Pacita L. Zara
Council for Health Research and Development
Gen. Santos Avenue
Bicutan, Taguig
Metro Manila


In order to immigrate as a permanent resident of the United States of America, you must first be granted an immigrant visa. Please contact the American Embassy, Consular Services Section, 1201 Roxas City, Manila 1000, for further information on applying for this visa. This is the first step in obtaining US citizenship. The Consular Services Section can also assist you with advice regarding any citizenship claim you may have.

Prior to requesting an application for a U.S. patent, the U.S. Department of Commerce, Patent and Trademark Office, suggests you first purchase the booklet, General Information Concerning Patents, for detailed information on the application filing process. This booklet is available for \$2.50 (payable in U.S. dollars) from the Superintendent of Documents, U.S. Government Printing Office, Washington, D.C. 20402. When your order this booklet, please refer to stock number 00300400659 5.

page 2
Mr. Patlingrao

I hope this information is helpful to you with your scientific studies. Your concern for people living with AIDS is very much appreciated.

Sincerely yours,

A handwritten signature in cursive script, appearing to read "Kristine M. Gebbie".

Kristine M. Gebbie, RN, MN
National AIDS Policy Coordinator

Enclosure

September 9, 1993

Dear Mr. Patlingrao:

Prior to requesting an application for a U.S. patent, the U.S. Department of Commerce, Patent and Trademark Office, suggests you first purchase the booklet, General Information Concerning Patents, for detailed information on the application filing process. This booklet is available for \$2.50 (payable in U.S. dollars) from the Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402. When your order this booklet, please refer to stock number 00300400659 5.

**FILE
COPY**

OFFICE	SURNAME	DATE	OFFICE	SURNAME	DATE	OFFICE	SURNAME	DATE

FILE
COPY

OFFICE	SURNAME	DATE	OFFICE	SURNAME	DATE	OFFICE	SURNAME	DATE

page 2
Mr. Patlingrao

I hope this information is helpful to you with your scientific studies. Your concern for people living with AIDS is very much appreciated.

Sincerely yours,

Kristine M. Gebbie, RN, MN
National AIDS Policy Coordinator

Prepared by: APO: NHazleton: 9/9/93: 632-1090: b:\philp.kmg

FILE
COPY

OFFICE	SURNAME	DATE	OFFICE	SURNAME	DATE	OFFICE	SURNAME	DATE

FILE
COPY

OFFICE	SURNAME	DATE	OFFICE	SURNAME	DATE	OFFICE	SURNAME	DATE

64 Carlock Street
Cebu City 6000
Philippines

July 19, 1993

draft reply

Kristine M. Gebbie
White House AIDS Coordinator
White House Office
1600 Pennsylvania Avenue, NW
Washington, DC 20500
U.S.A.

Dear Madam,

I am a scientist in the medical world. I would like to patent and deal my formula on the total treatment (not for temporary relief) of AIDS (Acquired Immune Deficiency Syndrome).

I understand that there are already 360 plus tests conducted by the U.S. Food and Drug Administration about the treatment on AIDS up to date. All failed. My formula is of different approach and different from all others. This is a proven formula and unknown to anybody in the medical profession. This formula has no baldness effect, safe and effective when used on its proper dose.

Help me to enter your country by sponsoring me as an scholar of your country or just help me become an Monorary Citizen of your country or anything that make my stay in your country permanently.

Please help the AIDS victim. There is nothing to lost if you believe on me and I can guarantee that this will never fail. I know with the help of the Almighty God soon this problem will be over. Remember, without Him, man is nothing.

Hoping for your favorable answer.

Yours sincerely,

Prospero R. Patlingrao

Prospero R. Patlingrao
(Medical Scientist)

Phone No. (32) 7-02-81

FINAL SCHEDULE
FOR
KRISTINE M. GEBBIE
National AIDS Policy Coordinator

DATE: September 9, 1993

PROPOSED BY: John Paul Gurrola

EVENT DATE: Friday, September 10, 1993

EVENT TIME: 10:00 A.M. TO 3:00 P.M.

LOCATION: Various locations within Washington, D.C.

PURPOSE: To introduce and inform the National AIDS Policy Coordinator (NAPC) to the AIDS-oriented facilities within Washington, D.C.

To provide an opportunity for the National AIDS Policy Coordinator to meet with the local press and answer their questions and discuss their needs.

BACKGROUND: Mr. Chris Bates, Executive Director of D.C. Care Consortium (202/543-5144) is co-sponsoring for this event.

In conjunction with the National AIDS Policy Office (NAPO), D.C. Care Consortium has selected five facilities that provide services related to HIV/AIDS to be visited. These five facilities have diversity both in relation to populations they serve and services provided.

The news conference will be held in the Frank D. Reeves Center for Municipal Affairs. The conference will be open press.

Traveling with the NAPC will be four to six members of the press, Dr. Athker, Commissioner of Public Health and Vincent Gray, Director Office of Human Services for the District. Gray and Athker have been encouraged to make brief comments at the press conference.

FINAL SCHEDULE
KRISTINE GEBBIE
SEPTEMBER 10, 1993
PAGE TWO

SEPTEMBER 10, 1993

10:00 A.M.	Depart 750 17th Street, N.W. (ONAPC) in route for D.C. Care Consortium 202/543-5144 (801 Pennsylvania Avenue, S.E. Suite 300).
10:20 A.M.	Arrive at D.C. Care Consortium. Greeted by H. Alexander Robinson, President, Dr. Patricia Hawkins, Secretary and Chris Bates, Executive Director.
10:30 A.M.	Depart for first site, Family and Medical Counseling Services, Inc. 2041 Martin Luther King Blvd., S.E. Suite 105.
10:45 A.M.	Arrive at Family and Medical Counseling Services, Inc. Greeted by Dr. Flora Hamilton, Director (202/889-7900). Tour facilities, meet with clients.
11:15 A.M.	Depart Family and Medical Counseling Services enroute for second site Inter-City AIDS Network (ICAN) 912 Third Street, N.W. (789-4226)
11:30 A.M.	Arrive at ICAN. Greeted by Thomas Gleaton, Director. Tour facilities, meet with clients.
12:00 P.M.	Depart ICAN enroute for third site IMPACT 300 Eye Street, N.E. Suite 300.
12:15 P.M.	Arrive at IMPACT. Greeted by Shirlene Showell, Director (202/546-7228). Tour facilities, meet with clients.
12:45 P.M.	Depart IMPACT enroute for fourth site SALUD 2701 Ontario Road, N.W. #2.
1:00 P.M.	Arrive at SALUD. Greeted by Alex Compangnet, Director (202/483-0842). Tour facilities, meet with clients. SALUD is supplying lunch for us at their site.
12:45 P.M.	Depart SALUD enroute for fifth site Whitman-Walker Clinic, Inc. 1407 S Street, N.W.
12:55 P.M.	Arrive at Whitman-Walker. Greeted by Jim Graham, Executive Director. Tour facilities, meet with clients.

FINAL SCHEDULE
KRISTINE GEBBIE
SEPTEMBER 10, 1993
PAGE THREE

1:35 P.M.	Depart Whitman-Walker enroute for the Frank D. Reeves Center for Municipal Affairs, 14th and U Street, N.W. Washington, D.C.
1:45 P.M.	Arrive at Reeves Center. Gebbie, Atkher, and Gray meet privately to discuss Washington, D.C. needs.
2:00 P.M.	Press conference begins. Brief remarks by NAPC, Athker and Gray. Brief Q&A by press.
2:40 P.M.	End press conference. Mix and mingle.
2:50 P.M.	Depart for 750 17th Street, N.W. (ONAPC)
3:00 P.M.	Arrive at ONAPC.

Withdrawal/Redaction Marker

Clinton Library

DOCUMENT NO. AND TYPE	SUBJECT/TITLE	DATE	RESTRICTION
001. letter	From: Kristine Gebbie; re: Diagnosis (1 page)	09/10/1993	b(6)

COLLECTION:

Clinton Presidential Records
National AIDS Policy Office
Kristine Gebbie
OA/Box Number: 3767

FOLDER TITLE:

September Chron Files 1993 [3]

2018-0756-F
jp4790

RESTRICTION CODES

Presidential Records Act - [44 U.S.C. 2204(a)]

- P1 National Security Classified Information [(a)(1) of the PRA]
- P2 Relating to the appointment to Federal office [(a)(2) of the PRA]
- P3 Release would violate a Federal statute [(a)(3) of the PRA]
- P4 Release would disclose trade secrets or confidential commercial or financial information [(a)(4) of the PRA]
- P5 Release would disclose confidential advice between the President and his advisors, or between such advisors [(a)(5) of the PRA]
- P6 Release would constitute a clearly unwarranted invasion of personal privacy [(a)(6) of the PRA]

C. Closed in accordance with restrictions contained in donor's deed of gift.

PRM. Personal record misfile defined in accordance with 44 U.S.C. 2201(3).

RR. Document will be reviewed upon request.

Freedom of Information Act - [5 U.S.C. 552(b)]

- b(1) National security classified information [(b)(1) of the FOIA]
- b(2) Release would disclose internal personnel rules and practices of an agency [(b)(2) of the FOIA]
- b(3) Release would violate a Federal statute [(b)(3) of the FOIA]
- b(4) Release would disclose trade secrets or confidential or financial information [(b)(4) of the FOIA]
- b(6) Release would constitute a clearly unwarranted invasion of personal privacy [(b)(6) of the FOIA]
- b(7) Release would disclose information compiled for law enforcement purposes [(b)(7) of the FOIA]
- b(8) Release would disclose information concerning the regulation of financial institutions [(b)(8) of the FOIA]
- b(9) Release would disclose geological or geophysical information concerning wells [(b)(9) of the FOIA]

Withdrawal/Redaction Marker

Clinton Library

DOCUMENT NO. AND TYPE	SUBJECT/TITLE	DATE	RESTRICTION
002. memo	George K. Degnon to Selected ASTHO [Association of State and Territorial Health Officials} Members; re: Diagnosis (1 page)	08/31/1993	b(6)

COLLECTION:

Clinton Presidential Records
National AIDS Policy Office
Kristine Gebbie
OA/Box Number: 3767

FOLDER TITLE:

September Chron Files 1993 [3]

2018-0756-F

jp4790

RESTRICTION CODES

Presidential Records Act - [44 U.S.C. 2204(a)]

- P1 National Security Classified Information [(a)(1) of the PRA]
- P2 Relating to the appointment to Federal office [(a)(2) of the PRA]
- P3 Release would violate a Federal statute [(a)(3) of the PRA]
- P4 Release would disclose trade secrets or confidential commercial or financial information [(a)(4) of the PRA]
- P5 Release would disclose confidential advice between the President and his advisors, or between such advisors [(a)(5) of the PRA]
- P6 Release would constitute a clearly unwarranted invasion of personal privacy [(a)(6) of the PRA]

C. Closed in accordance with restrictions contained in donor's deed of gift.

PRM. Personal record misfile defined in accordance with 44 U.S.C. 2201(3).

RR. Document will be reviewed upon request.

Freedom of Information Act - [5 U.S.C. 552(b)]

- b(1) National security classified information [(b)(1) of the FOIA]
- b(2) Release would disclose internal personnel rules and practices of an agency [(b)(2) of the FOIA]
- b(3) Release would violate a Federal statute [(b)(3) of the FOIA]
- b(4) Release would disclose trade secrets or confidential or financial information [(b)(4) of the FOIA]
- b(6) Release would constitute a clearly unwarranted invasion of personal privacy [(b)(6) of the FOIA]
- b(7) Release would disclose information compiled for law enforcement purposes [(b)(7) of the FOIA]
- b(8) Release would disclose information concerning the regulation of financial institutions [(b)(8) of the FOIA]
- b(9) Release would disclose geological or geophysical information concerning wells [(b)(9) of the FOIA]

THE WHITE HOUSE

WASHINGTON

September 10, 1993


Mr. Steve Michael
ACT UP Washington, D.C.
1337 14th Street, N.W.
Washington, D.C. 20005

Dear Steve:

Thank you for sharing the viewpoints and interests of D.C. ACT UP with me. The opportunity to explore potential differences and understand our mutual concerns are extremely important.

I look forward to a continued dialogue with you as the Office of National AIDS Policy moves into full gear.

Sincerely,

A handwritten signature in black ink, appearing to read "Kristine", with a stylized flourish at the end.

Kristine M. Gebbie, RN, MN
National AIDS Policy Coordinator

THE WHITE HOUSE

WASHINGTON

September 10, 1993


Mr. James Getty
ACT-UP Washington, D.C.
1337 14th Street, N.W.
Washington, D.C. 20005

Dear James:

Thank you for sharing the viewpoints and interests of D.C. ACT UP with me. The opportunity to explore potential differences and understand our mutual concerns are extremely important.

I look forward to a continued dialogue with you as the Office of National AIDS Policy moves into full gear.

Sincerely,

A handwritten signature in black ink, appearing to read "Kristine", with a stylized flourish at the end.

Kristine M. Gebbie, RN, MN
National AIDS Policy Coordinator

THE WHITE HOUSE

WASHINGTON

September 10, 1993

Mr. Wayne Turner
ACT UP Washington, D.C.
1337 14th Street, N.W.
Washington, D.C. 20005

Dear Wayne:

Thank you for sharing the viewpoints and interests of D.C. ACT UP with me. The opportunity to explore potential differences and understand our mutual concerns are extremely important.

I look forward to a continued dialogue with you as the Office of National AIDS Policy moves into full gear.

Sincerely,

A handwritten signature in dark ink, appearing to read "Kristine", with a stylized flourish at the end.

Kristine M. Gebbie, RN, MN
National AIDS Policy Coordinator

THE WHITE HOUSE
WASHINGTON


September 10, 1993

Mrs. Charlotte McGahan
1222 West State Street
Geneva, Illinois 60134

Dear Mrs. McGahan:

Thank you for writing. I am sorry if my remarks on the Today Show led you to believe that I advocated sexual activity for young people. I do not. But knowing that many teens are sexually active no matter what I say, and knowing that they are often uninformed on the risks of sex, or how to protect themselves, I support sound age-appropriate health education, including sexuality education and HIV information.

Sincerely,

A handwritten signature in dark ink, appearing to read "Kristine Gebbie", with a stylized, flowing script.

Kristine M. Gebbie, RN, MN
National AIDS Policy Coordinator

THE WHITE HOUSE

WASHINGTON

September 10, 1993

Mrs. Charlotte McGahan
1222 West State Street
Geneva, Illinois 60134

Dear Mrs. McGahan:

Thank you for writing. I am sorry if my remarks on the Today Show led you to believe that I advocated sexual activity for young people. I do not. But knowing that many teens are sexually active no matter what I say, and knowing that they are often uninformed on the risks of sex, or how to protect themselves, I support sound age-appropriate health education, including sexuality education and HIV information.

Sincerely,

Kristine M. Gebbie, RN, MN
National AIDS Policy Coordinator

Prepared by: APO: KMGebbie: gw: 9/9/93: 632-1090: b:\mcgahan.kg

FILE
COPY

OFFICE SURNAME	DATE	OFFICE SURNAME	DATE	OFFICE SURNAME	DATE

Thank you for
writing. I'm sorry
if my remarks on
the Today show led you
to believe I advocated
sexual activity for
young people. I do
not. But knowing
that many teens are
sexually active

No matter
what I say,
& knowing that
they are often
uninformed on
the risks of sex or
on how to protect
themselves, I
support second
age appropriate
health education
including sexuality
education information

THOMAS H. McGAHAN

360 East Randolph Street—

Suite 2607—

Chicago, Illinois 60601

(312) 819-1727

1325 N. State St.
Geneva, IL 60134

Dear Ms. Gebbe,

I heard part of your interview a month or two ago on the "Today Show". I was very concerned about some of your remarks.

If the public school system continues to head in the direction that the Clinton administration plans, my husband and I will be looking for an alternative for our young child. I started making inquiries immediately after hearing your comments.

Rather than condoning a sexually active lifestyle, why not teach children to be morally good and abstain from sex before marriage? That option was never mentioned.

Our nation is in a severe decline and things will only get worse unless we return to Biblical principles and righteous living.

Thank you

Charlotte McGahan


THOMAS H. McGAHAN

~~960 East Randolph Street~~

~~Suite 2607~~

~~Chicago, Illinois 60601~~

1225 N. State St.
Geneva, IL 60134



Ms. Christine Gebbe
The White House
1600 Pennsylvania Avenue
Washington, D.C. 20500

THE WHITE HOUSE

WASHINGTON

September 10, 1993

Mr. Lew Trenner
Trenner Laboratories
3046 Gaylord Street
Denver, Colorado 80210

Dear Mr. Trenner:


Thank you for writing, and for sharing information on the single use hypodermic syringe. It is essential that we investigate and develop methods that are effective in preventing transmission of HIV.

The Food and Drug Administration is responsible for the review and approval of any new medical device, and you should contact that Agency directly at the address listed below. The address is:

Mr. Dennis Meyers
Food and Drug Administration
Executive Secretariat (HF-40)
Parklawn Building, Room 16-70
5600 Fishers Lane
Rockville, Maryland 20857

Best wishes to you in your efforts. If you are ever in the Washington, D.C. area I would be happy to meet with you.

Sincerely,



Kristine M. Gebbie, RN, MN
National AIDS Policy Coordinator

THE WHITE HOUSE
WASHINGTON

September 10, 1993

Mr. Lew Trenner
Trenner Laboratories
3046 Gaylord Street
Denver, Colorado 80210

Dear Mr. Trenner:

Thank you for writing, and for sharing information on the single use hypodermic syringe. It is essential that we investigate and develop methods that are effective in preventing transmission of HIV.

The Food and Drug Administration is responsible for the review and approval of any new medical device, and you should contact that Agency directly at the address listed below. The address is:

Mr. Dennis Meyers
Food and Drug Administration
Executive Secretariat (HF-40)
Parklawn Building, Room 16-70
5600 Fishers Lane
Rockville, Maryland 20857

Best wishes to you in your efforts. If you are ever in the Washington, D.C. area I would be happy to meet with you.

Sincerely,

Kristine M. Gebbie, RN, MN
National AIDS Policy Coordinator

Prepared by: APO: TFox: 9/09/93: 690-5560: b:\foxltrs.gbe\trenner.gbe

FILE
COPY

OFFICE SURNAME	DATE	OFFICE SURNAME	DATE	OFFICE SURNAME	DATE

TRENNER LABORATORIES

3046 S. GAYLORD STREET • DENVER, COLORADO 80210

303-758-3565

27 August 1993

Ms. Kristine Gebbie
AIDS Policy Coordinator
c/o The White House
1600 Pennsylvania Ave., N.W.
Washington, DC 20500

Dear Ms. Gebbie:

By way of introduction, my name is Lew Trenner, President of Trenner Laboratories in Denver, Colorado. I am the inventor of and holder of the patent on a single-use, non-reusable syringe which, I believe, is capable of saving innumerable lives in the United States, and many more lives world-wide in a very short time span. These are lives which would otherwise have been lost to contaminated-needle-transmitted HIV virus.


A look at the patent, #4,979,943, dated December 25, 1990, will convince you that it is a mechanical bullwark against sharing contaminated syringes, which is a proven conductor of the HIV virus. This is not a theoretical devise, but rather one which you can see functioning.

Our job is to protect the healthy. The addicts have written their own destiny, and the medical profession has been working day and night with no definite progress. However, in the doing, they have consumed an estimated \$24.5 billion without curing one single human being.

Since there is no point in quoting statistics concerning the parameters of this epidemic to you, I have instead enclosed a list of countries and cities which have expressed an interest in purchasing this devise, along with copies of several of these letters. I have also enclosed a copy of my patent, as well as a simplified, expanded view of the devise.

Since I am now 82 years of age, and since many lives are lost on a daily basis to this plague, I hope you will give this mutually beneficial matter its due consideration as soon as possible. I look forward to hearing from you, as well as meeting with you at your earliest convenience.

Very truly yours,

A handwritten signature in dark ink, appearing to read 'Lew Trenner', with a large, sweeping flourish extending from the 'L'.

Lew Trenner

COLUMBIA
SPAIN
ISTANBUL, TURKEY
RYMCO (SO. AMERICA)
LAGOS (AGUDA)
CAMAROON
YOUNDE
NEW DELHI (INDIA)
HONDURAS
TANZANIA
SYRIA
SUNYANI (GHANA)
LEBANON
NIGERIA
BUENOS ARIES, ARGENTINA
ZIMBABWE
LIMA, PERU
MALAYSIA
GANGLI (INDONESIA)
FRANCE
ITALY
ISRAEL*
SWEDEN*
NETHERLANDS (HOLLAND)*
UNITED KINGDOM*
UNITED STATES*
CANADA*
MEXICO*
PHILIPPINES*
HAWAII, USA*
ALL ARAB STATES (SERVED THROUGH ISRAEL)*
POLAND*

*Needs
thanks -
offer to PDA
happy to meet
him if he
appears to be
in DC*

* ADDICTS ARE FORCED TO USE CONTAMINATED NEEDLES, DUE TO
LACK OF AVAILABILITY OF DISPOSABLE SYRINGES.

Messrs.

M & M ASSOCIATES

P.O. Box 748 Cheehalis

WA 98532 - UNITED STATES

ITALY

Milan, 16th October 1990

Kind attention Mr. M.L. FULLER

We acknowledge receipt with thanks your letter dated October 3rd, 1990.
We are in the process to implement a project concerning the production
of 250 millions disposable syringes not reusable.

The construction work will start in January 1991.

Although the type of syringes we are going to produce, is patented
Worldwide, we do not exclude the possibility to switch to more
economical or more efficient type if such is the case with your Hypotech
TM.

Therefore in order to assess the validity of your apparatus we would
appreciate to receiving a copy of your patent for examination and
comparison, and possibly one sample, after which we may eventually start
discussing licensing terms.

We do not see any chance, at least for the time being for the Autosert
TM.

Looking forward to receive your reply, we remain

Yours faithfully

Chairman
Eng. E. Pasquino
PHARMACHIM ENGINEERING SRL



fem gard, inc
4901 Bow Mar Dr., P.O. Box 391
Littleton CO 80123
USA

Date 09.09.92

Dear Sirs,

Our company is a manufacturer of disposable syringes in Turkey since 1977. There are several other companies in our group, that are involved in other branches of trade and industry.

As a growing company, our policy is to reach our customers with every possible product they may need. For this reason, we are looking for medical products that can be distributed and sold in Turkey.

At the moment, we are enjoying the #1 position in disposable syringe business, with a market share of 45%. We cover approximately 85% of all medical buyers, such as drugstores, pharmacies, wholesalers and hospitals. We are specially very successful in private and governmental tenders. Tibset's 91' turnover is over 12 million USD. We think that our current position in this market can easily explain the reason of our eagerness to find new products to add to our range.

If you are interested in our offer, we will be very happy to review your general catalog, to see if we can establish a good business relationship.

Yours Sincerely,
TIBSET Inc.

Metin Kastro
(Research Manager)

TRANSLATION

SHANGHAI RED STAR L...
CHONGMING SHANGHAI
CHINA WZ
10月15日

4

上海红星实业公司

Gentleman:

Our Industry Company is located
in Chongming of Shanghai.

We own 18 industrial enterprises.

We are very much interested in
your production licence of injector.

We shall greatly appreciate it
if you will kindly forward us some
relative details for our reference.

Thank you for your attention to
this matter and looking forward to
your early reply, we are,

yours truly
Jin Jianping
Managing Director.

地址: 崇明

电话: 228228接965451



OPTIMIT USA, INC.

TO: Dr. Lewis Trenner
FR: Prof. Alex Dely, Acting President
DA: February 5, 1993
RE: Possible Cooperation

CC: Harry Arkin, Esq.

Dear Dr. Trenner:

As the attached communication from Hans Schut, former Vice President of the Limburg Investment Bank in Englewood, indicates, we were just informed that you have developed and patented a disposable syringe.

Our company is the US arm of a 125 year old Czech company specialized in a wide variety of rubber/plastics products. Both the Czech and US firms have made the category of medical disposable plastic products a top expansion priority.

Optimit already produces 46 different types of plastic medical products (catheters of many types, etc), and we are presently working with the European Bank for reconstruction and Development regarding the setup of a syringe production facility to supply certain European and US markets.

If you still have interest in commercializing your syringe, we would appreciate hearing from you.

Best regards.

Alex

Attachment: Summary Optimit USA Product Listing

United States Patent [19]

Trenner

[11] Patent Number: 4,979,943

[45] Date of Patent: Dec. 25, 1990

[54] SINGLE USE HYPODERMIC SYRINGE

[76] Inventor: Lewis E. Trenner, 3046 Gaylord St.,
Denver, Colo. 80210

[21] Appl. No.: 493,971

[22] Filed: Mar. 15, 1990

[51] Int. Cl.³ A61M 5/00

[52] U.S. Cl. 604/110; 604/208

[58] Field of Search 604/110, 208, 210

[56] References Cited

U.S. PATENT DOCUMENTS

4,391,272	7/1983	Staempfli	604/110
4,493,703	1/1985	Butterfield	604/110
4,731,068	3/1988	Hesse	604/110
4,781,684	11/1988	Trenner	604/110

FOREIGN PATENT DOCUMENTS

8902287	3/1989	Switzerland	604/110
8904187	5/1989	Switzerland	604/110


Primary Examiner—Stephen C. Pellegrino





Assistant Examiner—Michael Rafa

[57] ABSTRACT

A single use hypodermic syringe is provided and has a reversible stop member which permits movement of the plug in one direction but not in the opposite direction so that the plug may be moved in the direction to aspirate fluid in the hypodermic syringe during which the reversing member moves into a reversing chamber so that it may be reversed to permit movement of the plug to eject fluid from the hypodermic syringe but to prevent movement of the plug in the opposite direction after the ejection of fluid has been commenced and after all of the fluid has been ejected.

20 Claims, 2 Drawing Sheets





SINGLE USE HYPODERMIC SYRINGE

FIELD OF THE INVENTION

This invention relates generally to the field of hypodermic syringes which are used to inject a desired fluid into the body for various purposes and more specifically to the field of a single use disposable hypodermic syringe which is particularly suited to prevent transmission of diseases from one body to another body.

BACKGROUND OF THE INVENTION

These are many instances wherein it is highly desirable that a hypodermic syringe be capable of only a single use. This occurs many times in hospitals or other areas of medical treatment. The present concern relative to the spread of Acquired Immune Deficiency Syndrome, commonly called AIDS, reaffirms the need for a single use hypodermic syringe. A problem that exists particularly in relation to drug addicts is that the means associated with the hypodermic syringe for permitting only a single use must be of a nature that the function thereof cannot be readily removed by the drug addict. Applicant has provided such a single use hypodermic syringe.

BRIEF DESCRIPTION OF THE INVENTION

This invention provides a single use hypodermic syringe having a reversible stop means for permitting movement of the plug means of the hypodermic syringe in one direction but preventing movement of the plug means in the opposite direction during the aspiration of fluid into the hypodermic syringe, and during or after the ejection of the fluid from the hypodermic syringe to prevent the reloading of the hypodermic syringe.

In a preferred embodiment of the invention, the hypodermic syringe comprises a barrel portion having a generally cylindrical inner surface and an integral reversing chamber having a cross-sectional configuration larger than the barrel portion formed from a plastic material. The reversing chamber has an end wall which is secured thereto by suitable means, such as by welding. Needle means are provided for permitting fluid to be drawn into or ejected from the barrel portion. The needle means comprise a plastic body having a hollow needle projecting outwardly therefrom. The plastic body portion has a generally cylindrical outer surface having a diameter slightly less than the diameter of the generally cylindrical inner surface of the barrel portion so that the plastic body portion may be inserted into the barrel portion and secured thereto by suitable means, such as by welding, to form a fluid tight seal between the inner and outer surfaces. Plug means are located within the barrel portion and are in sealing engagement with the generally cylindrical inner surface. Rod means are provided and comprise an elongated rod having the plug means releasably secured to one end thereof and a handle portion secured to the other end thereof. The elongated rod extends outwardly through an opening in the end wall of the reversing chamber so that the handle may be grasped to reciprocate the plug means to draw fluid into or eject fluid out of the main body portion. An abutment shoulder is formed on the elongated rod to contact the portions of the end wall of the reversing chamber surrounding the opening therein so as to limit the movement of the elongated rod in one direction. The cross-sectional configuration of the elongated rod and the opening cooperate to prevent rotation of the

elongated rod. Reversible stop means are mounted on the elongated rod between the plug means and the abutment shoulder and function to permit movement of the plug means in one direction but to prevent movement of the plug means in the opposite direction during the aspiration of fluid into the barrel portion and during or after the ejection of fluid from the barrel portion. The reversible stop means comprise a pin member having a central body portion located in an opening extending through the elongated rod for rotation about an axis transverse to the direction of movement of the elongated rod. Two integral leg portions extend outwardly from the opening in the elongated rod and when in the barrel portion, they extend in radial and axial directions and are in resilient contact with the generally cylindrical inner surface of the barrel portion.

The single use hypodermic syringe is marketed with the plug means in contact with or substantially in contact with the plastic body of the needle means with the ends of the leg portions facing the needle means. In operation, the hollow needle is placed into the desired fluid and the handle is pulled to aspirate the fluid into the barrel portion. The handle is pulled until the abutment shoulder prevents further movement thereof. At this position, the pin member is in the reversing chamber where it is free to rotate. When it is desired to eject the fluid from the barrel portion, the handle is pushed to move the plug means toward the needle means. As the elongated rod is moved, the leg portions contact the end of the generally cylindrical inner surface of the barrel portion and the central body portion of the pin member rotates so that the ends of the leg portions face the handle. During or after the ejection of the fluid from the barrel portion, the ends of the leg portions will prevent movement of the plug means in the aspiration direction by digging into the generally cylindrical inner surface.

BRIEF DESCRIPTION OF THE DRAWINGS

An illustrative and presently preferred embodiment of the invention is shown in the accompanying drawings in which:

FIG. 1 is a partially exploded elevational view with parts in section of a single use hypodermic syringe of this invention;

FIG. 2 is a cross-sectional view taken on the line 2—2 of FIG. 1;

FIG. 3 is an elevational view with parts in section illustrating a single use hypodermic syringe of this invention ready for use;

FIG. 4 is an elevational view with parts in section illustrating a single use hypodermic syringe of this invention after the fluid has been aspirated therein;

FIG. 5 is a cross-sectional view taken on the line 5—5 of FIG. 4;

FIG. 6 is an elevational view with parts in section illustrating a single use disposable hypodermic syringe of this invention during the ejection of the fluid; and

FIG. 7 is a cross-sectional view illustrating a different barrel portion.

DETAILED DESCRIPTION OF THE INVENTION

A single use disposable hypodermic syringe 2 is illustrated in the drawings and has a barrel portion 4 and a reversing chamber 6 integral therewith which are integrally molded using a plastic material, such as polypropylene or other plastic materials having similar charac-

teristics. The barrel portion 4 has a generally cylindrical inner surface 8 and first and second end portions 10 and 12. The reversing chamber 6 has a generally cylindrical inner surface 14 having a diameter greater than the diameter of the inner surface 8 for purposes described below. An end wall 16 having an opening 18 formed therein is secured to the reversing chamber by suitable means, such as by welding. A radially inwardly extending wall 20 extends between the inner surface 14 and the second end portion 12.

Needle means 30 are provided and comprise a plastic body portion 32 and a hollow needle 34 having a portion 36 thereof embedded in the plastic body portion 32. The plastic body portion 32 has a generally cylindrical outer surface portion 38 and a generally conical outer surface portion 40 which has a diameter greater than the diameter of the outer surface portion 38 to form an abutment shoulder 42. The diameter of the outer surface portion 38 is substantially the same as the diameter of the inner surface 8. The needle means 30 are secured to the first end portion 10 by inserting the outer surface portion 38 into the first end portion 10 until the abutment shoulder contacts the first end portion 10. Welding apparatus (not shown) is then used to weld the plastic body portion 32 to the first end portion in a fluid tight relationship. The plastic body portion 32, the barrel portion 4 and the reversing chamber 6 are preferably formed using the same type of plastic material such as a polypropylene or other plastic material having similar characteristics.

Plug means 50 are provided and comprise a body portion 52 having a pair 54 and 56 of radially outwardly projecting continuous cylindrical outer surfaces. Each of the outer surfaces 54 and 56 has a diameter slightly greater than the diameter of the inner surface 8 so as to be in a sealing relationship therewith. The plug means 50 are molded using a resilient material such as polybutadiene or polyisobutylene rubber. An elongated rod 58 having a non-circular cross-sectional configuration 60, such as a square, is provided and has a first end portion 62 which passes through the opening 18. The cross-sectional configuration of the opening 18 is the same as the cross-sectional configuration 60 of the elongated rod 58 to prevent rotation of the elongated rod 58. A spear head 64 is integral with a second end portion 66 of the elongated rod 58. The body portion 52 has a cylindrical passageway 68 leading to a cavity 70 which is dimensioned similarly to the spear head 64 so that it may be positioned therein. As illustrated in FIG. 1, the spear head 64 is larger than the passageway 68 so that the plug means 50 will move in either axial direction in the barrel portion 4 with the elongated rod 58. The passageway 68 and the cavity 70 cooperate with the spear head 64 to secure the plug means 50 to the elongated rod 58. A handle 72 is secured to the first end portion 62 by suitable means, such as by welding. An abutment shoulder 74 is formed on the elongated rod 58 and cooperates with the portions of the end wall 16 surrounding the opening 18 to limit the axial movement of the elongated rod 58. The elongated rod 58 is molded using a plastic material such as polypropylene or other materials having similar characteristics.

Reversible stop means 80 are provided and comprise a central body portion 82 having a cylindrical outer surface which is rotatably mounted in an opening 84 having a cylindrical inner surface extending through the elongated rod 58. The axial extent of the central body portion 82 is greater than the axial extent of the

opening 84 and the diameter of the cylindrical inner surface of the opening 84 is sufficiently larger than the diameter of the cylindrical outer surface of the central body portion 82 so that the central body portion 82 is freely rotatable in the opening 84. The opening 84 is located between the spear head 64 and the abutment shoulder 74. The central body portion 82 has integral leg portions 86 which, when the central body portion 82 is radially opposite to the inner surface 8, extend in radial and axial directions. Also, when the leg portions 86 are radially opposite to the inner surface 8, they are in resilient engagement therewith. The reversible stop means 80 is preferable formed from a metallic material, such as conventional piano wire, having a diameter of about 26-31 mils with the diameter of the opening 84 being about one mil greater to allow for free rotation of the central body portion 82. The distance between the leg portions 86 is greater than the diameter of the inner surface 8 but less than the diameter of the inner surface 14.

The hypodermic syringe 2 is assembled by cutting a radial slit (not shown) through the elongated rod 58 until it is in communication with the opening 84. Pressure is applied to the portions of the elongated rod 58 on opposite sides of the slit to open the slit so that the central body portion 82 can be moved through the slit into the opening 84. The end wall 16 is secured to the reversing chamber 6 by suitable means, such as by welding. The plug means 50 are then pushed onto the spear head 64 and the elongated rod 58 is then moved into and through the barrel portion 4, the reversing chamber 6 and the opening 18 in the end wall 16 while the plug means 50 moves into the first end portion 10. The needle means 30 are then placed against the plug means 50 and are pushed into the first end portion 10 and welded as described above. The handle 72 is then welded onto the first end portion 62. The assembled single use disposable hypodermic syringe 2 is illustrated in FIG. 3. The plug means 50 are in contact with or substantially in contact with the plastic body portion 32. The ends of the legs 86 are pointed toward the needle means 30 so that the plug means 50 can move in the direction of the arrow 88 but, when it has been moved away from the needle means 30, the plug means cannot be moved in the direction of the arrow 90.

In FIGS. 4 and 5, the single use disposable hypodermic syringe 2 is illustrated after it has been filled with the desired fluid 92. The abutment shoulder 74 has contacted the portions of the end wall 16 surrounding the opening 18 to prevent further movement of the plug means 50 in the direction of the arrow 88 so that the plug means 50 remain in the second end portion 12 and in sealing engagement with the inner surface 8. The reversible stop means 80 are located in the reversing chamber 6 so that the central body portion is free to rotate in the opening 84 and, as illustrated, has rotated so that the leg portions 86 are free to move. The axial length of leg portions 86, as illustrated in FIG. 3, is less than the axial distance between the radially inwardly extending wall 20 and the axis of rotation of the central body portion 82, as illustrated in FIG. 4, so that the leg portions 86 can move to the position illustrated in FIG. 4. As illustrated in FIG. 5, the distance between end portions 76 and 78 of the leg portions 86 is greater than the diameter of the inner surface 8 to ensure that the leg portions 86 are in resilient contact with the inner surface 8. In the position illustrated in FIG. 4, the single use

hypodermic syringe 2 is now ready to inject the fluid 92 into a body (not shown).

In FIG. 6, the single use hypodermic syringe 2 is illustrated at a location partially through the operation of injecting the fluid 92 into a body. As the elongated rod 58 is moved from the illustration in FIG. 4 in the direction of the arrow 90, the leg portions 86 contact the juncture of the second end portion 12 and the radially inwardly extending wall 20, and the continued movement of the elongated rod 58 causes the central body portion 82 to rotate in the opening 84 until the ends of the leg portions 86 are pointing towards the reversing chamber 6. In this position, the elongated rod 58 can move the plug means 50 in the direction of the arrow 90 but the elongated rod 58 and the plug means 50 cannot be moved in the direction of the arrow 88. Thus, the movement of the elongated rod 58 and the plug means 50, if stopped before the plug means 50 reaches the plastic body portion 32, the elongated rod and the plug means 50 cannot be moved in the direction of the arrow 88 so that no more fluid 92 can be aspirated into the barrel portion 4. Also, when the plug means 50 move into contact with the plastic body portion 32, any attempt to move the elongated rod 58 in the direction of the arrow 88 will only dig the ends 76 and 78 of the leg portions 86 into the inner surface 8 to prevent movement of the elongated rod in the direction of the arrow 88.

The barrel portion 4 may have indicia provided thereon so that dosages of the fluid less than the capacity of the barrel portion may be administered. This can be accomplished in several ways. In one way, the hollow needle 34 can be inserted into a supply of the fluid and the elongated rod can be pulled to aspirate the desired amounts of fluid into the barrel portion 4. The hollow needle 34 is then withdrawn and the elongated rod is pulled until the reversible stop means 80 are in the reversing chamber 6. The hypodermic syringe 2 is then held in an upright position and the air will move to the top of the barrel portion 4. The elongated rod 58 is then pushed until all the air is removed from the barrel portion 4. In another way, the hollow needle 34 is inserted into a supply of the fluid and the elongated rod 58 is pulled to fill the barrel portion 4. The elongated rod 58 is then pushed to return all but the desired dosage of the fluid to the supply of the fluid.

In FIG. 7, there is illustrated a barrel portion 4 having opposite axially extending grooves 94 formed in the inner surface 8 and adapted to receive the end portions 76 and 78 of the leg portions 86.

It is contemplated that the inventive concepts herein described may be variously otherwise embodied and it is intended that the appended claims be construed to include the alternative embodiments of the invention except insofar as limited by the prior art.

What is claimed is:

1. A single use hypodermic syringe comprising:
 - a hollow elongated barrel portion having a longitudinal axis, an inner surface and first and second end portions for use in providing a container for a fluid;
 - needle means connected to said first end portion for permitting fluid to be drawn into or ejected from said barrel portion;
 - plug means in sealing engagement with at least a portion of said inner surface and used to aspirate fluid into said barrel portion and to eject said fluid from said barrel portion;

rod means having said plug means secured thereto and having a portion thereof projecting outwardly from said second end portion of said barrel portion for use in reciprocating said plug means along said longitudinal axis;

reversible stop means for permitting movement of said plug means in one direction but preventing movement of said plug means in the opposite direction during the aspiration of fluid into said barrel portion and during or after the ejection of fluid from said barrel portion; and

wherein said reversible stop means comprise:

said rod means having an opening extending there-through, having a longitudinal axis extending in a direction transverse to said longitudinal axis of said barrel portion;

a rotatable stop member having a body portion located in said opening in said rod means for rotation about an axis transverse to the direction of movement of said plug means and at least one integral leg portion projecting radially and axially from said central body portion when said at least one integral leg portion is located within said barrel portion and said at least one integral leg portion being in resilient contact with said inner surface of said barrel portion; and

reversing means integral with said barrel portion for reversing said reversible stop means after said fluid has been aspirated into said barrel portion.

2. The invention as in claim 1 wherein said reversing means comprise:

a reversing chamber integral with said barrel portion; and

said reversing chamber having a cross-sectional configuration larger than the cross-sectional configuration of said reversible stop member when said leg portion projects only in the radial direction.

3. The invention as in claim 2 and further comprising: an end wall secured to said reversing chamber and having an opening formed therein;

said rod means passing through said opening; and said rod means substantially filling said opening.

4. The invention as in claim 3 and further comprising: stop means on said rod means for cooperating with the portions of said end wall surrounding said opening to limit the movement of said rod means.

5. The invention as in claim 3 and further comprising: rotation preventing means comprising a configuration of said rod means and said opening in said end wall for preventing rotation of said rod means.

6. The invention as in claim 1 wherein said reversible stop means comprise:

a central body portion located in an opening in said rod means for rotation about an axis transverse to the direction of movement of said plug means; said opening having opposite open ends; and

at least two leg portions, each of said leg portions projecting radially and axially from said central body portion through one of said openings and in resilient contact with said inner surface of said barrel portion.

7. A single use hypodermic syringe comprising:

a hollow elongated barrel portion having a longitudinal axis, an inner surface and first and second end portions for use in providing a container for a fluid; needle means connected to said first end portion for permitting fluid to be drawn into or ejected from said barrel portion;

plug means in sealing engagement with at least a portion of said inner surface and used to aspirate fluid into said barrel portion and to eject said fluid from said barrel portion;

rod means having said plug means secured thereto and having a portion thereof projecting outwardly from said second end portion of said barrel portion for use in reciprocating said plug means along said longitudinal axis;

reversible stop means for permitting movement of said plug means in one direction but preventing movement of said plug means in the opposite direction during the aspiration of fluid into said barrel portion and during or after the ejection of fluid from said barrel portion; and

wherein said reversible stop means comprise:

said rod means having an opening extending there-through, said opening having a longitudinal axis extending in a direction transverse to said longitudinal axis of said barrel portion;

a rotatable stop member having a central body portion located in said opening for rotation therein;

at least two integral leg portions, each of said leg portions projecting radially and axially from said central body portion when located within said barrel portion and being in resilient contact with said inner surface of said barrel portion; and

reversing means integral with said barrel portion for reversing said reversible stop means after said fluid has been aspirated into said barrel portion.

8. The invention as in claim 7 wherein said reversing means comprises:

a reversing chamber integral with said barrel portion; said reversing chamber having a cross-sectional configuration larger than the cross-sectional configuration of said inner surface of said barrel portion; and force applying means for applying a force on said leg portions so that they extend in an axial direction toward said reversing chamber after leaving said reversing chamber during said ejection of fluid from said barrel portion.

9. The invention as in claim 8 and further comprising: a pair of opposite longitudinally extending grooves in said inner surface of said barrel portion for receiving a portion of said legs.

10. The invention as in claim 7 wherein said needle means comprise:

a plastic body portion having a hollow needle projecting therefrom;

said plastic body portion having a generally cylindrical outer surface having a diameter slightly less than the diameter of said generally cylindrical inner surface of said barrel portion; and

sealing means for forming a fluid tight seal between said generally cylindrical inner and outer surfaces.

11. The invention as in claim 7 wherein:

said leg portions having end portions pointing toward said needle means during aspiration of said fluid into said barrel portion and pointing toward said

reversing means during the ejection of fluid from said barrel portion.

12. The invention as in claim 7 wherein:

said opening in said rod having a cylindrical inner surface; and

said central body portion having a cylindrical outer surface having a diameter slightly less than the diameter of said inner surface to permit rotation of said central body portion in said opening.

13. The invention as in claim 7 wherein:

said rotatable stop member is formed from a metallic material.

14. The invention as in claim 7 wherein said reversing means comprises:

a reversing chamber integral with said barrel portion; said reversing chamber having a cross-sectional configuration larger than the cross-sectional configuration of said reversible stop member when said leg portions project only in the radial direction; and said cross-sectional configuration and the axial length of said reversing chamber being great enough to permit said leg portions to rotate after they move out of contact with said inner surface of said barrel portion, to a position where they project only in the radial direction.

15. The invention as in claim 14 and further comprising: an end wall secured on said reversing chamber and having an opening therein

rotation preventing means comprising a configuration of said rod means and said opening in said end wall for preventing rotation of said rod means.

16. The invention as in claim 15 and further comprising:

said rod means passing through said opening; and said rod means substantially filling said opening.

17. The invention as in claim 16 and further comprising:

stop means on said rod means for cooperating with the portions of said end wall surrounding said opening to limit the movement of said rod means.

18. The invention as in claim 16 wherein said rotation preventing means comprises:

said rod means having a non-circular cross-sectional configuration; and

said opening in said end wall having a cross-sectional configuration similar to that of said rod means to prevent rotation of said rod means.

19. The invention as in claim 18 wherein:

said barrel portion and said reversing chamber are formed from a plastic material; and

said rotatable stop member is formed from a metallic material.

20. The invention as in claim 19 wherein said needle means comprises:

a plastic body portion having a hollow needle projecting therefrom;

said plastic body portion having a generally cylindrical outer surface having a diameter slightly less than the diameter of said generally cylindrical inner surface of said barrel portion; and

sealing means for forming a fluid tight seal between said generally cylindrical inner and outer surfaces.

* * * *

FIG 1




FIG 2




FIG 3

FIG 4




FIG 5




FIG 7





FIG 6



THE WHITE HOUSE
WASHINGTON

September 10, 1993


Ms. Sabrina Green
ACT UP Washington, D.C.
1337 14th Street, N.W.
Washington, D.C. 20005

Dear Sabrina:

Thank you for sharing the viewpoints and interests of D.C. ACT UP with me. The opportunity to explore potential differences and understand our mutual concerns are extremely important.

I look forward to a continued dialogue with you as the Office of National AIDS Policy moves into full gear.

Sincerely,



Kristine M. Gebbie, RN, MN
National AIDS Policy Coordinator

THE WHITE HOUSE
WASHINGTON

September 10, 1993

Ms. Cheryl Speaker
ACT UP Washington, D.C.
1337 14th Street, N.W.
Washington, D.C. 20005

Dear Cheryl:

Thank you for sharing the viewpoints and interests of DC ACT UP with me. The opportunity to explore potential differences and understand our mutual concerns are extremely important.

I look forward to a continued dialogue with you as the Office of National AIDS Policy moves into full gear.

Sincerely,

A handwritten signature in black ink, appearing to read "Kristine", with a stylized flourish at the end.

Kristine M. Gebbie, RN, MN
National AIDS Policy Coordinator

THE WHITE HOUSE
WASHINGTON

September 10, 1993


Mr. Michael Singerman
ACT UP Washington, D.C.
1337 14th Street, N.W.
Washington, D.C. 20005

Dear Michael:

Thank you for sharing the viewpoints and interests of D.C. ACT UP with me. The opportunity to explore potential differences and understand our mutual concerns are extremely important.

I look forward to a continued dialogue with you as the Office of National AIDS Policy moves into full gear.

Sincerely,

A handwritten signature in black ink, appearing to read "Kristine", with a stylized flourish at the end.

Kristine M. Gebbie, RN, MN
National AIDS Policy Coordinator

THE WHITE HOUSE

WASHINGTON

September 10, 1993

Dr. Charles E. Young, Chancellor
Chancellor's Office
2147 Murphy Hall
University of California, Los Angeles
405 Hilgard Avenue
Los Angeles, California 90024-1405

Dear Chancellor Young:


The news reports and information available to me regarding plans to reorganize the health professional schools at UCLA have been very disturbing.

I write this letter as an alumna of the School of Nursing (MN, 1968), a former School of Nursing faculty member (1969-1971; Regent's Lecturer, 1990), and a long-time professional colleague of many, both in the School of Nursing and School of Public Health.

The changes confronting the health and illness fields today are immense. From all that is occurring today, and proposed for the future, we need the best and brightest minds. Further, the field of health is clearly multi-disciplinary; the expertise represented in public health and nursing are in increasing demand. A major health science university should elevate these disciplines and skills, rather than de-emphasize them. Building toward the future requires the full scope of undergraduate and graduate training in nursing, and the coordinated work of the various public health disciplines.

If I can provide any further information, or be of any assistance to you as you explore options, I would be pleased to do so.

Sincerely,



Kristine M. Gebbie, RN, MN
National AIDS Policy Coordinator

Page 2 - Dr. Charles E. Young, Chancellor

CC:

Dr. Jack W. Peltason
Dr. Walter Massey
Mr. Howard H. Leach
The Honorable Pete Wilson

BCC:

Dr. Ada M. Lindsey
Dr. A. A. Afifi

September 10, 1993

Ms. Eleanor D. Acheson
Assistant Attorney General
for the Office of Policy Development
U.S. Department of Justice, Room 4234
Constitution Avenue and 10th Street, N.W.
Washington, D.C. 20530

Dear Assistant Attorney General Acheson:

In a recent meeting between Attorney General Reno and Kristine Gebbie, National AIDS Policy Coordinator, Ms. Reno identified you as her lead contact on the complex issue of HIV control programs. I am your counterpart within the Office of the AIDS Policy Coordinator.

Our most pressing issue, and one closely identified with the spread of the disease amongst women and children, is that of needle and syringe (NS) exchanges within the intravenous drug using (IDU) populations.

Ms. Reno asked for our office to supply the Department with information and key "talking points" on these issues. Enclosed is a "talking points" paper on Needle Exchange Programs (NEP) and I have enclosed the latest and most succinct book on the topic. If you can read no other chapter because of the press of time, I would draw your attention to Larry Gostin's chapter on Law and Policy. However, I think that you will find the entire book an easy read on a complex subject.

I will contact your office within the next ten days to schedule an appointment to meet with you. I would be more than happy to come to the Department.

Sincerely,


Ben Merrill JD
Special Assistant to the Coordinator

bcc: Kristine Gebbie

THE WHITE HOUSE

WASHINGTON

September 7, 1993

The Honorable Janet F. Reno
U.S. Department of Justice
Constitution Avenue and 10th Street, N.W.
Washington, D.C. 20530

Dear Attorney General Reno:


I appreciate having a few minutes of your time to begin discussions of how we might work together on HIV-related policies.

Information and key "talking points" on issues of civil rights associated with the AIDS epidemic will be available to your office shortly. I appreciate your willingness to include some of these "points" in your presentations as a reinforcement.

My office will have materials on syringe and needle exchange programs as a strategy in HIV control programs available in advance of any inter-departmental meetings on the subject. I appreciate your identification of Eleanor D. Acheson, Assistant Attorney General for the Office of Policy Development, as a lead contact on this complex issue.

I look forward to working with you. Please let me know if I can be of any assistance to you or your staff.

Sincerely,

A handwritten signature in dark ink, appearing to read "Kristine", written in a cursive style.

Kristine M. Gebbie, RN, MN
National AIDS Policy Coordinator

Withdrawal/Redaction Marker

Clinton Library

DOCUMENT NO. AND TYPE	SUBJECT/TITLE	DATE	RESTRICTION
003. letter	From: Kristine Gebbie; re: Diagnosis [Duplicate of 001] (1 page)	09/10/1993	b(6)

COLLECTION:

Clinton Presidential Records
National AIDS Policy Office
Kristine Gebbie
OA/Box Number: 3767

FOLDER TITLE:

September Chron Files 1993 [3]

2018-0756-F

jp4790

RESTRICTION CODES

Presidential Records Act - [44 U.S.C. 2204(a)]

- P1 National Security Classified Information [(a)(1) of the PRA]
- P2 Relating to the appointment to Federal office [(a)(2) of the PRA]
- P3 Release would violate a Federal statute [(a)(3) of the PRA]
- P4 Release would disclose trade secrets or confidential commercial or financial information [(a)(4) of the PRA]
- P5 Release would disclose confidential advice between the President and his advisors, or between such advisors [(a)(5) of the PRA]
- P6 Release would constitute a clearly unwarranted invasion of personal privacy [(a)(6) of the PRA]

C. Closed in accordance with restrictions contained in donor's deed of gift.

PRM. Personal record misfile defined in accordance with 44 U.S.C. 2201(3).

RR. Document will be reviewed upon request.

Freedom of Information Act - [5 U.S.C. 552(b)]

- b(1) National security classified information [(b)(1) of the FOIA]
- b(2) Release would disclose internal personnel rules and practices of an agency [(b)(2) of the FOIA]
- b(3) Release would violate a Federal statute [(b)(3) of the FOIA]
- b(4) Release would disclose trade secrets or confidential or financial information [(b)(4) of the FOIA]
- b(6) Release would constitute a clearly unwarranted invasion of personal privacy [(b)(6) of the FOIA]
- b(7) Release would disclose information compiled for law enforcement purposes [(b)(7) of the FOIA]
- b(8) Release would disclose information concerning the regulation of financial institutions [(b)(8) of the FOIA]
- b(9) Release would disclose geological or geophysical information concerning wells [(b)(9) of the FOIA]

Withdrawal/Redaction Marker

Clinton Library

DOCUMENT NO. AND TYPE	SUBJECT/TITLE	DATE	RESTRICTION
004. memo	George K. Degnon to Selected ASTHO [Association of State and Territorial Health Officials] Members; re: Diagnosis [Duplicate of 002] (1 page)	08/31/1993	b(6)

COLLECTION:

Clinton Presidential Records
National AIDS Policy Office
Kristine Gebbie
OA/Box Number: 3767

FOLDER TITLE:

September Chron Files 1993 [3]

2018-0756-F
jp4790

RESTRICTION CODES

Presidential Records Act - [44 U.S.C. 2204(a)]

- P1 National Security Classified Information [(a)(1) of the PRA]
- P2 Relating to the appointment to Federal office [(a)(2) of the PRA]
- P3 Release would violate a Federal statute [(a)(3) of the PRA]
- P4 Release would disclose trade secrets or confidential commercial or financial information [(a)(4) of the PRA]
- P5 Release would disclose confidential advice between the President and his advisors, or between such advisors [(a)(5) of the PRA]
- P6 Release would constitute a clearly unwarranted invasion of personal privacy [(a)(6) of the PRA]

C. Closed in accordance with restrictions contained in donor's deed of gift.

PRM. Personal record misfile defined in accordance with 44 U.S.C. 2201(3).

RR. Document will be reviewed upon request.

Freedom of Information Act - [5 U.S.C. 552(b)]

- b(1) National security classified information [(b)(1) of the FOIA]
- b(2) Release would disclose internal personnel rules and practices of an agency [(b)(2) of the FOIA]
- b(3) Release would violate a Federal statute [(b)(3) of the FOIA]
- b(4) Release would disclose trade secrets or confidential or financial information [(b)(4) of the FOIA]
- b(6) Release would constitute a clearly unwarranted invasion of personal privacy [(b)(6) of the FOIA]
- b(7) Release would disclose information compiled for law enforcement purposes [(b)(7) of the FOIA]
- b(8) Release would disclose information concerning the regulation of financial institutions [(b)(8) of the FOIA]
- b(9) Release would disclose geological or geophysical information concerning wells [(b)(9) of the FOIA]

Withdrawal/Redaction Marker

Clinton Library

DOCUMENT NO. AND TYPE	SUBJECT/TITLE	DATE	RESTRICTION
005. letter	The Ervin's to Dear Friends; re: Diagnosis (1 page)	08/14/1993	b(6)

COLLECTION:

Clinton Presidential Records
National AIDS Policy Office
Kristine Gebbie
OA/Box Number: 3767

FOLDER TITLE:

September Chron Files 1993 [3]

2018-0756-F
jp4790

RESTRICTION CODES

Presidential Records Act - [44 U.S.C. 2204(a)]

- P1 National Security Classified Information [(a)(1) of the PRA]
- P2 Relating to the appointment to Federal office [(a)(2) of the PRA]
- P3 Release would violate a Federal statute [(a)(3) of the PRA]
- P4 Release would disclose trade secrets or confidential commercial or financial information [(a)(4) of the PRA]
- P5 Release would disclose confidential advice between the President and his advisors, or between such advisors [(a)(5) of the PRA]
- P6 Release would constitute a clearly unwarranted invasion of personal privacy [(a)(6) of the PRA]

C. Closed in accordance with restrictions contained in donor's deed of gift.

PRM. Personal record misfile defined in accordance with 44 U.S.C. 2201(3).

RR. Document will be reviewed upon request.

Freedom of Information Act - [5 U.S.C. 552(b)]

- b(1) National security classified information [(b)(1) of the FOIA]
- b(2) Release would disclose internal personnel rules and practices of an agency [(b)(2) of the FOIA]
- b(3) Release would violate a Federal statute [(b)(3) of the FOIA]
- b(4) Release would disclose trade secrets or confidential or financial information [(b)(4) of the FOIA]
- b(6) Release would constitute a clearly unwarranted invasion of personal privacy [(b)(6) of the FOIA]
- b(7) Release would disclose information compiled for law enforcement purposes [(b)(7) of the FOIA]
- b(8) Release would disclose information concerning the regulation of financial institutions [(b)(8) of the FOIA]
- b(9) Release would disclose geological or geophysical information concerning wells [(b)(9) of the FOIA]

THE WHITE HOUSE
WASHINGTON

September 10, 1993


Mr. John L. LeBlanc
President
International Stamp Art
P.O. Box 827
Spartanburg, South Carolina 29304

Dear Mr. LeBlanc:

Thank you for writing, and for sharing information about your product. I have shared your letter and materials with the AIDS Action Council and the National Association of People with AIDS. I hope this will be of help.

Thank you for your kind wishes and good luck in your efforts.

Sincerely,



Kristine M. Gebbie, RN, MN
National AIDS Policy Coordinator

CC:

AIDS Action Council
National Association of People With AIDS

THE WHITE HOUSE
WASHINGTON

September 10, 1993

Mr. John L. LeBlanc
President
International Stamp Art
P.O. Box 827
Spartanburg, South Carolina 29304

Dear Mr. LeBlanc:

Thank you for writing, and for sharing information about your product. I have shared your letter and materials with the AIDS Action Council and the National Association of People with AIDS. I hope this will be of help.

Thank you for your kind wishes and good luck in your efforts.

Sincerely,

Kristine M. Gebbie, RN, MN
National AIDS Policy Coordinator

CC:

AIDS Action Council
National Association of People With AIDS

Prepared by: APO: TFox: 9/9/93:202-690-5560:b:\foxlts.gbe\leblanc.gbe

FILE
COPY

OFFICE	SURNAME	DATE	OFFICE	SURNAME	DATE	OFFICE	SURNAME	DATE

I N T E R N A T I O N A L S T A M P A R T



MAILING ADDRESS: P.O. BOX 827 • SPARTANBURG, SC 29304
145 NORTH CHURCH STREET • SPARTANBURG, SC 29301
TELEPHONE: 803-591-4225
WATS # 800-833-5514
TELEX: (USA) 5106011593 FAX # 803-591-4255

September 6, 1993

Ms. Kristine Gebbie
Presidential Aids Commission
200 Independence Avenue, S.W.
Room 725 H
Washington, DC 20201

Dear Ms. Gebbie:

Please allow me to introduce our firm.

Over the past eight years, we have been developing the concept of offering enlarged reproductions of US postage stamps, under our license agreement with the US Postal Service. My reason for writing you is to make you aware of our existence.

Given the new US postage stamp being issued to commemorate AIDS Awareness, I have a twofold request for your assistance:


1. Will you make our existence known to anyone who might be interested in creating some fund-raising approach to/through the use of this stamp image? and
2. Can you provide a listing of AIDS-interested organizations that we might approach on a direct basis?

The enclosed information offers an idea of our firm, and our products.

Thank you for your assistance. Please accept my best wishes for great success in your new position. I believe that the entire nation wishes you well.

Good luck!

Cordially,



John L. LeBlanc
President

JLL:rss



I N T E R N A T I O N A L S T A M P A R T

MODERN MINIATURE ART

Throughout modern history, postage stamps have reflected each country's own unique history, culture, natural beauty and famous people and places.

The images found on postage stamps have introduced people to our country's great statesmen, eminent scholars, important principles, critical achievements and historic anniversaries.

From an aesthetic viewpoint, these mini-works of art serve as beautiful decorations for our mailings, bringing art, beauty and education into every American's life.

Each year, the US Postal Service receives nearly 20,000 suggestions for potential stamp subjects...an incredible number, when only two or three dozen suitable subjects are selected annually. The results are translated into 40 billion stamps per year.

Since 1985, International Stamp Art has been pioneering the founder's concept of Stamp Art™, the belief that these small works of art have a place in America's homes and offices, reproduced as copyrighted enlargements of the full-color postage stamp image.

Dr. Doug Lewis, Curator of Sculpture for the National Gallery of Art, and a member of the Citizen's Committee, perhaps said it best: "...stamps are important to society. We are recording for the world a lasting tribute to an important person, place or achievement. We are recognizing — and creating — a part of America's heritage."

International Stamp Art creates affordable, unique collectibles from these miniature works of art, capable of carrying your message, and of communicating it with impact!



I N T E R N A T I O N A L S T A M P A R T

THE COMPANY

Founded in 1985, International Stamp Art is an official licensee of the United States Postal Service. We are licensed to produce collectible art products, utilizing the images found on US postage stamps.

Our products offer an unusual adaption of an everyday product — the common postage stamp — reproduced in full color enlargement as collectible art products.

Each of our products is produced under specific license agreement with the stamp-issuing authority, either foreign or domestic. Among our license agreements are these authorities:

The United States Postal Service
The US Department of the Interior
[Federal Duck Stamp]
The National Wild Turkey Federation
The Pan American Games/Indianapolis
The Principality of Liechtenstein
Guyanan Post & Telecommunications
The Republic of South Korea
The Republic of Italy
The Republic of Portugal
The Australian Post
Jersey Postal Administration
Pasadena Tournament of Roses

All of our products are submitted to the proper authorities for approval prior to their offering. This is an important aspect of our license agreement, but our experience of the past years had made this quite routine, and we have yet to have approval withheld for any reason.

The company trades on our ability to offer a first quality product at affordable pricing; our ability to “marry” a particular stamp image to the needs of the client, drawing upon a considerable range of subjects, and the flexibility to match product to promotional budgets via adjustments of paper stock, printing methods, varying product size, etc.



I N T E R N A T I O N A L S T A M P A R T

STAMP ART™

International Stamp Art has created this trade name.

It is used on all of our products, and has been registered with the U.S. Trademark Department. Permission is available, via written request/approval, for usage of the trademarked name, with proper credit, in conjunction with an offer of our product(s).

COPYRIGHTS

The United States Postal Service warrants that they hold the copyright on all stamp designs of the US Postal Service. This right remains with the United States Postal Service, and is so indicated on every product.

International Stamp Art takes and holds a derivative copyright on the design of the individual product featuring the copyrighted stamp image.

ROYALTIES

As a condition of its license, International Stamp Art is responsible for the payment of royalties to the US Postal Service. This responsibility remains with International Stamp Art.

Upon occasion, certain stamp subjects require additional license approval. In such cases — with the exception of the Olympic Games — we acquire the necessary agreement, and are responsible for these additional royalties.



I N T E R N A T I O N A L S T A M P A R T

THE PRODUCTS

FINE ART POSTER

Our 18" x 24" first quality poster is lithographed on acid-free, neutral pH, 80# cover stock. We choose to utilize fade-resistant inks in the production process, often in as many as six to eight colors.

Imprinting of client name/logo is available at no extra charge, if desired.
Framing of the posters is available at extra charge, if desired.

HIGH VOLUME POSTER

Our 17½" x 24" poster is lithographed on a 70# text weight paper, intended for usage in promotions requiring large print runs. Printed via the four color process method, it is more economical for quantity usage.

Imprinting of client name/logo is available at no extra charge, if desired.

FINE ART PRINT

This 11" x 14" art print is lithographed on first quality archival art paper, also on an acid-free cover stock. It offers ease of fulfillment and handling, due to its size.

Decorative matting, supportive backing board and shrink-wrapping for protection are offered as options on this product. It is also possible to combine several (4 or 5) of these prints into a handsome portfolio, encased within a Presentation Folder.

Imprinting of client name/logo is available at no extra charge, if desired.
Framing of the art prints is available at extra charge, if desired.

PERSONAL NOTE CARDS

Our first quality note cards and envelopes measure 4¼" x 5½" when folded. We offer eight cards/envelopes per polybag package as a general rule, but are capable of structuring varying package quantities, as desired. Printed on a 65# laid cover stock paper.

Imprinting of client name/logo is available at no extra charge, if desired.

continued



I N T E R N A T I O N A L S T A M P A R T

THE PRODUCTS

LIMITED EDITION PRINT

Intended as a top quality executive gift, this 12" x 18" image is printed on acid-free archival art paper in full color. We then purchase and affix the actual stamp being reproduced, strike it with a special cancellation mark, and number each print individually. Included with each print are Certification Papers attesting to the rarity of the print, which is then encased within a special Presentation Folder.

Imprinting of client name/logo is available at no extra charge, if desired.
Framing of the Limited Edition prints is available at extra charge, if desired.

Clinton Presidential Records Digital Records Marker

This is not a presidential record. This is used as an administrative marker by the William J. Clinton Presidential Library Staff.

This marker identifies the place of a publication.

Publications have not been scanned in their entirety for the purpose of digitization. To see the full publication please search online or visit the Clinton Presidential Library's Research Room.

T H E

Stamp ArtTM

C O L L E C T I O N



Stamp Art™ © 1989, International Stamp Art, a non-exclusive licensee of the United States Postal Service
Stamp Design © 1988, United States Postal Service

Based upon early 20th Century New England and Pennsylvania folk art, this lovebird design is the ninth in the popular "Love" series of postage stamp designs.

Clinton Library Transfer Form

Case #, if applicable	2018-0756-F	Accession #		
Collection/Record Group	Clinton Presidential Records	Series/Staff Member	Kristine Gebbie	
Subgroup/Office of Origin	National AIDS Policy Office	Subseries		
Folder Title	September Chron Files 1993	OA/ID Number	3767	Box Number
Description of Item(s)	Posters of 2 Postage Stamps: 1) Migratory Bird Hunting and Conservation Stamp 2) May 23, 1788 South Carolina Stamp			

Donor Information				
Last Name:	First Name:	Middle Name:	Title:	
Affiliation:	Phone (Wk):	Phone (Hm):		
Street:	City:	State (or Country):	Zip:	

Transferred to:	Other	Transfer Point	During Processing
Other (Specify):	End of collection in oversized box	New Location	End of collection
Transferred by:	Debbie Bush	Date of Tranfer	5/1/2019
Received by:		Date of Receipt	

THE WHITE HOUSE
WASHINGTON

7294
Chae file
#

September 10, 1993


Terry A. Maroney
HIV-Related Violence Program Coordinator
New York City Gay and Lesbian
Anti-Violence Project
208 West 13th Street
New York, New York 10011

Dear Terry:

Thank you for sharing the HIV-Related Violence Resource Manual. It is an impressive compilation of information and advice. If your project publishes an annual report, I would appreciate seeing it.

Best wishes.

Sincerely,



Kristine M. Gebbie, RN, MN
National AIDS Policy Coordinator

resource
mail +
incoming
being use.
②

THE WHITE HOUSE
WASHINGTON



TERRY A. MARONEY
HIV-RELATED VIOLENCE
PROGRAM COORDINATOR

NEW YORK CITY GAY AND LESBIAN
ANTI-VIOLENCE PROJECT

September 10, 1993

208 WEST 13 STREET
NEW YORK, N.Y. 10011

OFFICE: (212) 807-6761
FAX: (212) 807-1044
HOTLINE: (212) 807-0197

Terry A. Maroney
HIV-Related Violence Program Coordinator
New York City Gay and Lesbian
Anti-Violence Project
208 West 13th Street
New York, New York 10011

Dear Terry:

Thank you for sharing the HIV-Related Violence Resource Manual. It is an impressive compilation of information and advice. If your project publishes an annual report, I would appreciate seeing it.

Best wishes.

Sincerely,

Kristine M. Gebbie, RN, MN
National AIDS Policy Coordinator

Prepared by: APO: KMGebbie: gw: 9/6/93: 632-1090: b:\maroney.kg

FILE
COPY

OFFICE	SURNAME	DATE	OFFICE	SURNAME	DATE	OFFICE	SURNAME	DATE

Dear Terry

Thank you for sharing the
HIV-Related Violence Resource
Manual. It is an impressive
~~overhead~~ compilation of
information and advice. If
your project ~~get~~ publishes in
annual report, I'd appreciate
seeing it. Best wishes. Sincerely

THE WHITE HOUSE

WASHINGTON

September 10, 1993

Mahlon Johnson, M.D., Ph.D.
Assistant Professor of Pathology
Vanderbilt University School of Medicine
and the Veterans Administration Medical Center
C-3321 Medical Center North
Nashville, Tennessee 37232


Dear Dr. Johnson:

Thank you for writing and for your interest in contributing to the nationwide effort to stop the spread of HIV. I admire your generosity and resolve towards this end.

In the near future we will be assembling a variety of committees and work groups to develop an effective response to the epidemic. I will certainly keep you in mind for any activities that would make use of your expertise, experience, and perceptions.

Again, thank you for writing and I will look forward to working with you.

Sincerely,

A handwritten signature in cursive script, appearing to read "Kristine M. Gebbie".

Kristine M. Gebbie, RN, MN
National AIDS Policy Coordinator

THE WHITE HOUSE
WASHINGTON

September 10, 1993

Mahlon Johnson, M.D., Ph.D.
Assistant Professor of Pathology
Vanderbilt University School of Medicine
and the Veterans Administration Medical Center
C-3321 Medical Center North
Nashville, Tennessee 37232

Dear Dr. Johnson:

Thank you for writing and for your interest in contributing to the nationwide effort to stop the spread of HIV. I admire your generosity and resolve towards this end.

In the near future we will be assembling a variety of committees and work groups to develop an effective response to the epidemic. I will certainly keep you in mind for any activities that would make use of your expertise, experience, and perceptions.

Again, thank you for writing and I will look forward to working with you.

Sincerely,

Kristine M. Gebbie, RN, MN
National AIDS Policy Coordinator

Prepared by: APO: TFox: 9/9/93: 690-5560: b:\foxltrs.gbe\johnson.gbe

FILE
COPY

OFFICE	SURNAME	DATE	OFFICE	SURNAME	DATE	OFFICE	SURNAME	DATE

Withdrawal/Redaction Marker

Clinton Library

DOCUMENT NO. AND TYPE	SUBJECT/TITLE	DATE	RESTRICTION
006. letter	To: John H. Gibbons; re: Grant (1 page)	08/26/1993	b(6)

COLLECTION:

Clinton Presidential Records
National AIDS Policy Office
Kristine Gebbie
OA/Box Number: 3767

FOLDER TITLE:

September Chron Files 1993 [3]

2018-0756-F
jp4790

RESTRICTION CODES

Presidential Records Act - [44 U.S.C. 2204(a)]

- P1 National Security Classified Information [(a)(1) of the PRA]
- P2 Relating to the appointment to Federal office [(a)(2) of the PRA]
- P3 Release would violate a Federal statute [(a)(3) of the PRA]
- P4 Release would disclose trade secrets or confidential commercial or financial information [(a)(4) of the PRA]
- P5 Release would disclose confidential advice between the President and his advisors, or between such advisors [(a)(5) of the PRA]
- P6 Release would constitute a clearly unwarranted invasion of personal privacy [(a)(6) of the PRA]

C. Closed in accordance with restrictions contained in donor's deed of gift.

PRM. Personal record misfile defined in accordance with 44 U.S.C. 2201(3).

RR. Document will be reviewed upon request.

Freedom of Information Act - [5 U.S.C. 552(b)]

- b(1) National security classified information [(b)(1) of the FOIA]
- b(2) Release would disclose internal personnel rules and practices of an agency [(b)(2) of the FOIA]
- b(3) Release would violate a Federal statute [(b)(3) of the FOIA]
- b(4) Release would disclose trade secrets or confidential or financial information [(b)(4) of the FOIA]
- b(6) Release would constitute a clearly unwarranted invasion of personal privacy [(b)(6) of the FOIA]
- b(7) Release would disclose information compiled for law enforcement purposes [(b)(7) of the FOIA]
- b(8) Release would disclose information concerning the regulation of financial institutions [(b)(8) of the FOIA]
- b(9) Release would disclose geological or geophysical information concerning wells [(b)(9) of the FOIA]

Withdrawal/Redaction Marker

Clinton Library

DOCUMENT NO. AND TYPE	SUBJECT/TITLE	DATE	RESTRICTION
007. letter	To: Kristine Gebbie; re: Physician/Educator (1 page)	08/14/1993	b(6)

COLLECTION:

Clinton Presidential Records
National AIDS Policy Office
Kristine Gebbie
OA/Box Number: 3767

FOLDER TITLE:

September Chron Files 1993 [3]

2018-0756-F
jp4790

RESTRICTION CODES

Presidential Records Act - [44 U.S.C. 2204(a)]

- P1 National Security Classified Information [(a)(1) of the PRA]
- P2 Relating to the appointment to Federal office [(a)(2) of the PRA]
- P3 Release would violate a Federal statute [(a)(3) of the PRA]
- P4 Release would disclose trade secrets or confidential commercial or financial information [(a)(4) of the PRA]
- P5 Release would disclose confidential advice between the President and his advisors, or between such advisors [(a)(5) of the PRA]
- P6 Release would constitute a clearly unwarranted invasion of personal privacy [(a)(6) of the PRA]

C. Closed in accordance with restrictions contained in donor's deed of gift.

PRM. Personal record misfile defined in accordance with 44 U.S.C. 2201(3).

RR. Document will be reviewed upon request.

Freedom of Information Act - [5 U.S.C. 552(b)]

- b(1) National security classified information [(b)(1) of the FOIA]
- b(2) Release would disclose internal personnel rules and practices of an agency [(b)(2) of the FOIA]
- b(3) Release would violate a Federal statute [(b)(3) of the FOIA]
- b(4) Release would disclose trade secrets or confidential or financial information [(b)(4) of the FOIA]
- b(6) Release would constitute a clearly unwarranted invasion of personal privacy [(b)(6) of the FOIA]
- b(7) Release would disclose information compiled for law enforcement purposes [(b)(7) of the FOIA]
- b(8) Release would disclose information concerning the regulation of financial institutions [(b)(8) of the FOIA]
- b(9) Release would disclose geological or geophysical information concerning wells [(b)(9) of the FOIA]

Withdrawal/Redaction Marker

Clinton Library

DOCUMENT NO. AND TYPE	SUBJECT/TITLE	DATE	RESTRICTION
008. resume	[Personally Identifiable Information] [Partial] (1 page)	08/03/1993	b(6)

COLLECTION:

Clinton Presidential Records
National AIDS Policy Office
Kristine Gebbie
OA/Box Number: 3767

FOLDER TITLE:

September Chron Files 1993 [3]

2018-0756-F
jp4790

RESTRICTION CODES

Presidential Records Act - [44 U.S.C. 2204(a)]

- P1 National Security Classified Information [(a)(1) of the PRA]
- P2 Relating to the appointment to Federal office [(a)(2) of the PRA]
- P3 Release would violate a Federal statute [(a)(3) of the PRA]
- P4 Release would disclose trade secrets or confidential commercial or financial information [(a)(4) of the PRA]
- P5 Release would disclose confidential advice between the President and his advisors, or between such advisors [(a)(5) of the PRA]
- P6 Release would constitute a clearly unwarranted invasion of personal privacy [(a)(6) of the PRA]

C. Closed in accordance with restrictions contained in donor's deed of gift.

PRM. Personal record misfile defined in accordance with 44 U.S.C. 2201(3).

RR. Document will be reviewed upon request.

Freedom of Information Act - [5 U.S.C. 552(b)]

- b(1) National security classified information [(b)(1) of the FOIA]
- b(2) Release would disclose internal personnel rules and practices of an agency [(b)(2) of the FOIA]
- b(3) Release would violate a Federal statute [(b)(3) of the FOIA]
- b(4) Release would disclose trade secrets or confidential or financial information [(b)(4) of the FOIA]
- b(6) Release would constitute a clearly unwarranted invasion of personal privacy [(b)(6) of the FOIA]
- b(7) Release would disclose information compiled for law enforcement purposes [(b)(7) of the FOIA]
- b(8) Release would disclose information concerning the regulation of financial institutions [(b)(8) of the FOIA]
- b(9) Release would disclose geological or geophysical information concerning wells [(b)(9) of the FOIA]

CURRICULUM VITAE

MAHLON D. JOHNSON, M.D., PH.D.

CLINTON LIBRARY PHOTOCOPY

NAME: Mahlon D. Johnson
OFFICE ADDRESS: Department of Pathology
OFFICE PHONE NUMBER: (615) 322-3998
DATE AND PLACE OF BIRTH: 
SOCIAL SECURITY NO.: 

PERSONAL DATA:

Home Address: 715 Lynnbrook Road
Nashville, TN 37215
Home Phone Number: 297-8197
Marital Status: Single
Number of Children: None
Military Service: None

[008]

EDUCATION:

1972-1977 B.A. University of Tennessee
1977-1981 M.D. University of Tennessee Center for the Health Sciences
1980-1984 Ph.D. University of Tennessee Center for the Health Sciences
(Pharmacology)
1984 Research Fellow (4 months)
Department of Cell Biology, Dr. W.S.T. Griffin
University of Texas Health Sciences Center, Dallas
1984-1987 Resident in Anatomic Pathology
Vanderbilt University School of Medicine
1987-1989 Fellow in Neuropathology
Vanderbilt University School of Medicine
1989-1992 Research Fellow, Department of Cell Biology
Dr. Harold L. Moses, Preceptor
Vanderbilt University, School of Medicine

LICENSURE AND CERTIFICATION:

Tennessee (Current)

BOARD CERTIFICATION:

1988	Diplomate, American Board of Pathology, Anatomic Pathology
1989	Diplomate, American Board of Pathology, Neuropathology

ACADEMIC APPOINTMENTS:

1989-1991	Instructor in Pathology, Vanderbilt University
1991-present	Assistant Professor of Pathology, Vanderbilt University
1991-present	Visiting Neuropathologist, Univ. of Tenn. Mem. Res. Ctr., Knoxville, TN
1992-present	Assistant Professor of Cell Biology, Vanderbilt University

HOSPITAL APPOINTMENTS:

1989-present	Staff, Vanderbilt Hospital
1991-present	Staff, Veterans Administration Medical Center, Nashville, TN

PROFESSIONAL AND TEACHING ACTIVITIES:

Neuropathologist, Vanderbilt CNS AIDS Project
Lecturer, Vanderbilt Medical School Pathology Course 501

TRAINEES:

1991-present	Megumi, Horiba, M.D., Assistant Prof. of Neurology, Tokyo Women's Medical College
--------------	---

HONORS:

1976	Phi Kappa Phi
1980	Alpha Omega Alpha Medical Honor Society
1984	Sigma Xi Excellence in Research Award
1982-1984	NIH National Research Service Award

RESEARCH SUPPORT:

1. Career Development Award (Research Associate), Veterans Administration. Jan. 1991-Dec. 1994, "Growth Factor Regulation of Arachnoid and Meningiomas."
2. Principal Investigator. Merit Award, Veterans Administration. Oct. 1991-Oct. 1994. "Growth Factor Regulation of Arachnoid and Meningiomas."
3. Co-P.I., Amer. Cancer Society (Pending). "Role of TGF β and its Receptors in Human Breast Epithelial Cells."

ARTICLES IN REFEREED JOURNALS:

1. Crowley, W.R., Terry, L.C., and Johnson, M.D. Evidence for the involvement of central epinephrine systems in the regulation of luteinizing hormone, prolactin and growth hormone release in female rats. *Endocrinology* 110:1102-1107, 1982.
2. Terry, L.C., Crowley, W.R., and Johnson, M.D. Control of episodic growth hormone release by the central epinephrine system. *Studies in the chronically cannulated rats. Journal of Clinical Investigation* 69:104-112, 1982.
3. Johnson, M.D., and Crowley, W.R. Serotonin turnover in individual brain nuclei: evaluation of three methods using liquid chromatography with electrochemical detection. *Life Science* 31:589-595, 1982.
4. Adler, B.A., Johnson, M.D., Lynch, C.O., and Crowley, W.R. Evidence that norepinephrine and epinephrine systems mediate the stimulatory effects of ovarian hormones on luteinizing hormone and luteinizing hormone release hormone. *Endocrinology* 113:1431-1438, 1983.
5. Terry, L.C., Crowley, W.R., Lynch, C., Longserre, C., and Johnson, M.D. Role of central epinephrine systems in regulation of anterior pituitary hormone secretion. *Peptides* 3:311-318, 1982.
6. Johnson, M.D., and Crowley, W.R. Acute effects of estradiol on luteinizing hormone, prolactin and serotonin turnover in individual brain nuclei. *Endocrinology* 113:1935-1941, 1983.
7. Johnson, M.D., and Crowley, W.R. Effects of opiate antagonists on serotonin turnover and on luteinizing hormone and prolactin secretion in estrogen or morphine treated rats. *Neuroendocrinology* 38:322-327, 1984.
8. Lynch, C.O., Johnson, M.D., and Crowley, W.R. Effects of serotonin agonist, quipazine on luteinizing hormone and prolactin release: evidence for serotonin—catecholamine interactions. *Life Science* 35:1481-1487, 1984.

9. Johnson, M.D., Whetsell, W.O., and Crowley, W.R. Quinolinc acid stimulates luteinizing hormone secretion in female rats: Evidence for involvement of N-methyl-D-aspartate-preferring receptors. *Experimental Brain Research* 59:57-61, 1985.
10. Johnson, M.D., Carroll, B., Whetsell, W.O., and Crowley, W.R. Quinolinc acid stimulates luteinizing hormone secretion through a serotonin-dependent mechanism. *Experimental Brain Research* 59:62-67, 1985.
11. Johnson, M.D., and Crowley, W.R. Effects of ovarian hormones on serotonin turnover in individual hypothalamic nuclei. *Endocrinology* 118:1180-1187, 1986.
12. Johnson, M.D., Newman, J.H., and Baxter, J.W. Neuroleptic malignant syndrome presenting as adult respiratory distress syndrome and disseminated intravascular coagulation. *Southern Medical Journal* 81:543-545, 1988.
13. Johnson, M.D., Gray, M.E., and Stahlman, M.T. Calcitonin gene-related peptide in human fetal lung and in neonatal lung disease. *J. Histochem. Cytochem.* 36:199-204, 1988.
14. Johnson, M.D., Glick, A.D., and Davis, B.W. Immunohistochemical evaluation of Leu-7, myelin basic protein, S-100, glial fibrillary acidic protein and LN-3 immunoreactivity in nerve sheath tumors and sarcomas. *Arch. Pathol. Lab. Med.* 112:155-160, 1988.
15. Johnson, M.D., Glick, A.D., and Whetsell, W.O. Congenital hypomyelinating polyneuropathy with associated central nervous system hypomyelination: Report of an autopsied case. *Clin. Neuropath.* 8:28-34, 1989.
16. Johnson, M.D., Davis, B.D., and Wetherall, N.T. Production and molecular characterization of proto-oncogene expressing tumors for *in situ* hybridization and immunohistochemical studies. *J. Exp. Path., Toxicol., Oncol.* 9:171-200, 1989.
17. Johnson, M.D., Maciunas, R., Dutt, P., Clinton, M.E., and Collins, R. Granulomatous angitis diagnosed by magnetic resource imaging-directed stereotactic biopsy in a patient with lymphocyte-predominant Hodgkin's disease. *Surg. Neurol.* 24:587-590, 1989.
18. Johnson, M.D., Tulipan, N., and Whetsell, W.O. Osteoblastic meningioma of the fourth ventricle. *Neurosurgery* 24:587-590, 1989.
19. Johnson, M.D., Gray, M.E. Carpenter, G., Pepinsky, R.B., Sundell, H., and Stahlman, M.T. Ontogeny of epidermal growth factor receptor/kinase and of lipocortin-1 in the fetal ovine lungs. *Ped. Res.* 25:535-541, 1989.
20. Johnson, M.D., Kamso-Pratt, J., Federspiel, C.F., and Whetsell, W.O. Mast cell and lymphoreticular infiltrates in neurofibromas: A comparison with nerve sheath tumors. *Arch. Pathol. Lab. Med.* 113:1263-1270, 1989.

21. Johnson, M.D., Kamso-Pratt, J., Whetsell, W.O., and Pepinsky, R.B. Lipocortin-1 immunoreactivity in the normal human central nervous system and lesions with astrocytosis. *Am. J. Clin. Pathol.* 92:424-429, 1989.
22. Johnson, M.D., Kamso-Pratt, J., Pepinsky, R.B., and Whetsell, W.O. Lipocortin-1 immunoreactivity in central and peripheral nervous system glial tumors. *Human Pathol.* 20:772-776, 1989.
23. Johnson, M.D., Gray, M.E., Carpenter, G., Pepinsky, R.B., and Stahlman, M.T. Ontogeny of epidermal growth factor receptor/kinase and of lipocortin-1 in the fetal and neonatal human lungs. *Human Pathol.* 21:182-191, 1990.
24. Johnson, M.D., Lavin, P., and Whetsell, W.O. Fulminant monophasic multiple sclerosis, Marburg's type. *J. Neurol. Neurosurg. Psych.* 53:918-921, 1990.
25. Johnson, M.D., Gray, M.E., Pepinsky, R.B., and Stahlman, M.T. Lipocortin-1 immunoreactivity in the human pituitary gland. *J. Histochem. Cytochem.* 38:1841-1845, 1990.
26. Pelton, R.W., Johnson, M.D., Saxena, B., Perrett, B.A., Moses, H.L., and Gold, L.I. Expression of TGF β 1, β 2, β 3 mRNA and protein in the murine lung. *Amer. J. Resp. Cell Mol. Biol.* 5:522-530, 1991.
27. Asadourian L.L.H., Bailly, C., Brunat-Mentigny, M., Ebrahim, S.A.D., Favrot, M., Fontaniere, B., Jennings, M.T., Jennings, V.D.L., Johnson, M.D., Keremens, B., Lapras, G., Philip, I., Philip, T., Pialat, J., Shapiro, J.R., Tabone, E., and Turc-Carel, C. *In vitro* karyotypic and immunophenotypic characterization of primitive neuroectodermal tumors: similarities to malignant gliomas. *European J. Cancer.* (In Press.)
28. Arteaga, C.L., Johnson, M.D., Page, D.L., Coffey, R.J., Carpenter, G., and Todderud, G.G. Overexpressing phospholipase C-1 in primary human breast carcinomas. *Proc. Natl. Acad. Sci. (USA)* 88:10435-10439, 1991.
29. Johnson, M.D., Federspiel, C.F., Gold, L.I., and Moses, H.L. TGF β and TGF β receptor expression in human meningioma cells. *Am. J. Path.* 141:633-641, 1992.
30. Bosque, P., Vnencak-Jones, C., Johnson, M., and McLean, M. A PrP gene condon 178 case substitution and a 24 bp interstitial deletion in familial Creutzfeldt-Jacob disease. *Neurology* 42:1864-1870, 1992.
31. Johnson, M.D., Gold, L.I., and Moses, H.L. Evidence for TGF- β expression in human leptomeningeal cells and TGF β -like activity in human cerebrospinal fluid. *Lab. Invest.* 67:360-368, 1992.
32. Johnson, M.D., Jennings, M.T., Gold, L.I., and Moses, H.L. Transforming growth factor B in neural embryogenesis and neoplasia. *Human Pathol.* 93:2405-2410, 1993.

33. Jennings, M.T., Slatkin, N., D'Angelo, M., Ketonen, L., Johnson, M.D., Rosenblum, M., Creasy, J., Tulipan, N., and Walker, R. Neoplastic meningitis as the presentation of occult primitive neuroectodermal tumors. *J. Neurooncol.* (In Press.)
34. Johnson, M.D., Horiba, M., and Arteaga, C.L. The epidermal growth factor receptor-kinase is associated with phospholipase C- γ in meningiomas. (Submitted.)
35. Johnson, M.D., Maciunas, R., and Collins, R.D. Granulomatous angiitis presenting as a solitary cerebellar lesion. (Submitted.)
36. Arteaga, C.L., Hurd, S.D., Winnier, A.R., Johnson, M.D., Fordly, B.M. and Forbes, J.T. Anti-transforming growth factor (TGF)- β antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity: Evidence for an indirect role of TGF β in human cancer progression. (Submitted.)
37. Pierce, D.F., Johnson, M.D., Matsui, Y., Robinson, S.D., Gold, L.I., Purchio, A.F., Daniel, C.W., Hogan, B.L.M., Moses, H.L. Inhibition of mammary duct development but not alveolar outgrowth during pregnancy in MMTA-TGF β 1 5223/225 transgenic mice. (Submitted.)
38. Johnson, M.D., Serafin, W.F., Horiba, M., Moses, H.L. Immortalized mast cells selectively synthesize TGF β 1. (Submitted.)

THE WHITE HOUSE
WASHINGTON

September 10, 1993

Don Des Jarlis, Ph.D.
National Commission on AIDS
BIMCIRDRI
11 Beach Street
New York, New York 10013

Dear Dr. ~~Jarlis~~:

Thank you so much for joining me, Dr. Phil Lee and others in the review of the Healthy People 2000 HIV objectives. Your participation helped underscore our collective need to have an open process of selecting goals and defining workable strategies.

As I indicated toward the end of the meeting, any additional ideas, suggestions, inspirations, criticisms or alternatives you have would be most appreciated. Just send them to me and I will see that they are shared with all involved.

Again, my thanks for making time to attend this important meeting. I look forward to working with you as we move to the next phase in this process.

Sincerely,



Kristine M. Gebbie, RN, MN
National AIDS Policy Coordinator

These are all
prepared by
J. Messore.

9/9/93.

THE WHITE HOUSE
WASHINGTON

September 10, 1993

Mark Magenheim, M.D.
CDC AIDS Advisory Committee
Director and Health Officer
Saragota County Public Health Unit
2200 Ringling Blvd.
Saragota, Florida 34237


Dear Dr. Magenheim:

Thank you so much for joining me, Dr. Phil Lee and others in the review of the Healthy People 2000 HIV objectives. Your participation helped underscore our collective need to have an open process of selecting goals and defining workable strategies.

As I indicated toward the end of the meeting, any additional ideas, suggestions, inspirations, criticisms or alternatives you have would be most appreciated. Just send them to me and I will see that they are shared with all involved.

Again, my thanks for making time to attend this important meeting. I look forward to working with you as we move to the next phase in this process.

Sincerely,



Kristine M. Gebbie, RN, MN
National AIDS Policy Coordinator

THE WHITE HOUSE

WASHINGTON

September 10, 1993

John Arradondo, M.D.
7511 Moondance Lane
Houston, Texas 77071-2619


Dear Dr. Arradondo:

Thank you so much for joining me, Dr. Phil Lee and others in the review of the Healthy People 2000 HIV objectives. Your participation helped underscore our collective need to have an open process of selecting goals and defining workable strategies.

As I indicated toward the end of the meeting, any additional ideas, suggestions, inspirations, criticisms or alternatives you have would be most appreciated. Just send them to me and I will see that they are shared with all involved.

Again, my thanks for making time to attend this important meeting. I look forward to working with you as we move to the next phase in this process.

Sincerely,




Kristine M. Gebbie, RN, MN
National AIDS Policy Coordinator

THE WHITE HOUSE
WASHINGTON

September 10, 1993

Mr. Moises Agosto
National Minority AIDS Council
300 I Street N.E.
Suite 400
Washington, D.C. 20002


Dear Mr. Agosto 

Thank you so much for joining me, Dr. Phil Lee and others in the review of the Healthy People 2000 HIV objectives. Your participation helped underscore our collective need to have an open process of selecting goals and defining workable strategies.

As I indicated toward the end of the meeting, any additional ideas, suggestions, inspirations, criticisms or alternatives you have would be most appreciated. Just send them to me and I will see that they are shared with all involved.

Again, my thanks for making time to attend this important meeting. I look forward to working with you as we move to the next phase in this process.

Sincerely,



Kristine M. Gebbie, RN, MN
National AIDS Policy Coordinator

THE WHITE HOUSE
WASHINGTON

September 10, 1993

Ms. Madeleine Kunin
Deputy Secretary of Education
400 Maryland Avenue S.W., Room 4015
Washington, D.C. 20202


Dear Ms. Kunin:

Thank you so much for attending the September 7th review of Healthy People 200 objectives for HIV infection. While only two of the objectives specifically mention educational institutions, many others can only be achieved with the full collaboration of health education interests.

Your questions and comments indicate that you are already well aware of the many stumbling blocks to progress, including negative community perceptions about HIV and substance abuse and efforts to polarize the debate rather than focus on those more centrist approaches that can serve to get us started.

I look forward to working with you and other key staff in the Department of Education as I move forward with a new national AIDS policy effort. If you have any questions, or if I can be of any assistance to the Department of Education, please let me know.

Sincerely,



Kristine M. Gebbie, RN, MN
National AIDS Policy Coordinator

THE WHITE HOUSE

WASHINGTON

September 10, 1993

Mr. Dennis Whalen
National Alliance of State and Territorial AIDS Directors
Executive Deputy Director AIDS Institute
New York State Department of Health
Empire State Plaza
Corning Tower, Room 342
Albany, New York 12237

Dear Mr. Whalen:

Thank you so much for joining me, Dr. Phil Lee and others in the review of the Healthy People 2000 HIV objectives. Your participation helped underscore our collective need to have an open process of selecting goals and defining workable strategies.

As I indicated toward the end of the meeting, any additional ideas, suggestions, inspirations, criticisms or alternatives you have would be most appreciated. Just send them to me and I will see that they are shared with all involved.

Again, my thanks for making time to attend this important meeting. I look forward to working with you as we move to the next phase in this process.

Sincerely,




Kristine M. Gebbie, RN, MN
National AIDS Policy Coordinator

THE WHITE HOUSE
WASHINGTON

September 10, 1993

Ms. Christine Lubinski
National Organizations Responding to AIDS
AIDS Action Council
1875 Connecticut Avenue, Suite 700
Washington, D.C. 20009


Dear Ms. Lubinski 

Thank you so much for joining me, Dr. Phil Lee and others in the review of the Healthy People 2000 HIV objectives. Your participation helped underscore our collective need to have an open process of selecting goals and defining workable strategies.

As I indicated toward the end of the meeting, any additional ideas, suggestions, inspirations, criticisms or alternatives you have would be most appreciated. Just send them to me and I will see that they are shared with all involved.

Again, my thanks for making time to attend this important meeting. I look forward to working with you as we move to the next phase in this process.

Sincerely,



Kristine M. Gebbie, RN, MN
National AIDS Policy Coordinator

THE WHITE HOUSE

WASHINGTON

September 10, 1993

Nancy M. Valentine, Ph.D., RN, CNAA, FAAN
Assistant Chief Medical Director
for Nursing Programs
Department of Veterans Affairs
Veterans Health Administration
Washington, D.C. 20420


Dear Dr. Valentine:

Thank you for kind words of congratulations, and your offer of assistance as I take on my new responsibilities as the National AIDS Policy Coordinator.

Nurses are key participants in today's fast changing health world. As providers of care, as managers of health systems, as policy makers and researchers, nurses make a difference! Reform of our health care system and improvement of our National AIDS policy will benefit from that difference.

I appreciate hearing from you and will certainly keep the cadre of dedicated VA nurses in mind for any collaborative activities that would make use of their considerable expertise and experience.

Sincerely,



Kristine M. Gebbie, RN, MN
National AIDS Policy Coordinator

THE WHITE HOUSE
WASHINGTON

September 10, 1993

Nancy M. Valentine, Ph.D., RN, CNAA, FAAN
Assistant Chief Medical Director
for Nursing Programs
Department of Veterans Affairs
Veterans Health Administration
Washington, D.C. 20420

Dear Dr. Valentine:

Thank you for kind words of congratulations, and your offer of assistance as I take on my new responsibilities as the National AIDS Policy Coordinator.

Nurses are key participants in today's fast changing health world. As providers of care, as managers of health systems, as policy makers and researchers, nurses make a difference! Reform of our health care system and improvement of our National AIDS policy will benefit from that difference.

I appreciate hearing from you and will certainly keep the cadre of dedicated VA nurses in mind for any collaborative activities that would make use of their considerable expertise and experience.

Sincerely,

Kristine M. Gebbie, RN, MN
National AIDS Policy Coordinator

Prepared by: APO: TFox: 9/09/93: 690-5560: b:\foxltrs.gbe\valentine.gbe

FILE
COPY

OFFICE	SURNAME	DATE	OFFICE	SURNAME	DATE	OFFICE	SURNAME	DATE



DEPARTMENT OF VETERANS AFFAIRS
Veterans Health Administration
Washington DC 20420

August 26, 1993

In Reply Refer To: 118

Ms. Kristine M. Gebbe
AIDS Policy Coordinator
Department of Health and Human Services
750 17th Street, N.W.
Washington, D.C. 20500

Dear Ms. Gebbe:

On behalf of the Nursing Service of the Department of Veterans Affairs, I would like to extend congratulations on your appointment as the nation's first AIDS Policy Coordinator. The commitment of President Clinton to addressing the AIDS crisis has provided much needed hope to the many people affected by this tragic epidemic. It is with great pride that we note the President's selection of a health care leader who is a nurse to serve in his vanguard!

VA nurses provide a wide range of services to veterans with AIDS. They have been instrumental in establishing excellent programs in prevention, clinical care and research throughout the country. This cadre of dedicated and expert nurses is valued highly, and would welcome the opportunity to work with you.

Best wishes for success as you begin this challenging position.

Sincerely,

Nancy M. Valentine, Ph.D, RN, CNAA, FAAN
Assistant Chief Medical Director
for Nursing Programs

*Needs
Thank you
look forward
to collaborating*

THE WHITE HOUSE
WASHINGTON

Ray —

I was asked to deliver a message
to the President —

I suggest a very brief
reply of "thanks for writing"
I've referred your letter
to Kristine Gehlrich, Nat'l
AIDS Policy Coordinator, &

Thanks

Kristine

Rec'd. from 750 on 9/3/93
Sent out on "

MICHAEL MONTANI
65 EAST BAYVIEW RD
DENNIS, MA 02638
508 385-6618

PRESIDENT WILLIAM CLINTON
THE WHITE HOUSE

JULY 12, 1993

DEAR MR. PRESIDENT,

A CURE FOR AIDS!

YES IT IS TRUE MR. PRESIDENT! THERE IS A CURE THAT IS CURRENTLY BEING STALLED BY THE FDA. IT IS CALLED OZONE/ OXYGEN GAS. OZONE HAS BEEN USED IN EUROPE FOR DECADES. IT IS NONTOXIC AND OFFERS HELP TO THE SICK INDIVIDUAL FOR MANY DIFFERENT DISEASES.

OZONE HAS BEEN PATENTED IN THE US BY MEDIZONE INTERNATIONAL INC. (MZEI). MZEI HAS BEEN WORKING FOR SEVEN YEARS TO GET INTO HUMAN TRIALS BUT THEY ARE STALLED AT EVERY JUNCTURE!

MR. PRESIDENT, I PRAY THAT YOU WILL HAVE TIME TO READ THIS LETTER AND THE ENCLOSURES. FOR THE SAKE OF ALL THE AIDS PATIENTS WITH NO HOPE, I BEG YOU TO INTERCEDE WITH THE FDA. WITH YOUR INTERCESSION, HUMAN TRIALS COULD BE BROUGHT TO FRUITION.

IT IS CURRENTLY BEING USED SUCCESSFULLY IN MIAMI AND OTHER UNDERGROUND LOCATIONS AROUND THE COUNTRY. PEOPLE ARE SURVIVING WITH ITS' USE. I SIT IN A WHEELCHAIR WITH AN INTERNAL CATHETER. I CAN ONLY DREAM OF THE DAY WHEN I WILL WALK AGAIN EVEN RUN WITH NO LEG BAG ON. I HAVE MULTIPLE SCLEROSIS AND I WOULD LIKE TO SEE WHAT OZONE CAN DO FOR ME. THAT'S RIGHT! I AM NOT WORRIED ABOUT RISKS I JUST WANT TO TRY IT!

I HAVE FURTHER DOCUMENTATION IF YOU REQUIRE IT I WOULD BE MOST HAPPY TO FORWARD IT TO YOU. MR. PRESIDENT, IF I CAN BE OF ANY FURTHER ASSISTANCE OR IF I CAN ANSWER ANY QUESTIONS PLEASE DO NOT HESITATE TO CALL OR WRITE.

SINCERELY,

MICHAEL MONTANI

ENCLS

CC:

HILLARY CLINTON, HEALTH CARE TASK FORCE CHAIRMAN

THE WHITE HOUSE
WASHINGTON

Carole -

I hope the attached
letter can be
sent by the
President -
Let me know if there
are questions.

Kristine Gehl

August 31, 1993

Draft

Robert E. Allen
Chairman and CEO
AT&T
295 N. Maple Avenue
Basking Ridge, New Jersey 07920

Dear Mr. Allen:

The care and concern which you and the people of AT&T have shown in response to HIV/AIDS set high standards for the rest of the nation. Congratulations on those accomplishments, and for the splendid description in the July/August issue of Focus of how you are dealing with AIDS in the workplace.

The growing corporate leadership response to AIDS is impressive, and I commend you and AT&T for being in the vanguard.

Thank you.

Sincerely,

Bill Clinton

THE WHITE HOUSE
WASHINGTON


September 13, 1993

Mr. Zimmerman
Vantage Press, Inc.
516 West 34th Street
New York, New York 10001

Dear Mr. Zimmerman:

You have my permission to use the quotation from the Sanitorian,
December, 1989, in the forthcoming book, Experiences in
Environmental Sanitation.

Sincerely,

A handwritten signature in black ink, appearing to read "Kristine Gebbie". The signature is fluid and cursive, with a large initial "K" and a long, sweeping underline.

Kristine M. Gebbie, RN, MN
National AIDS Policy Coordinator

cc: Mr. William B. Culham

THE WHITE HOUSE
WASHINGTON

September 13, 1993

Mr. Zimmerman
Vantage Press, Inc.
516 West 34th Street
New York, New York 10001

Dear Mr. Zimmerman:

You have my permission to use the quotation from the Sanitorian,
December, 1989, in the forthcoming book, Experiences in
Environmental Sanitation.

Sincerely,

Kristine M. Gebbie, RN, MN
National AIDS Policy Coordinator

cc: Mr. William B. Culham

Prepared by: APO: KMGebbie: gw: 9/9/93: 632-1090: b:\zimmerma.kg

FILE
COPY

OFFICE	SURNAME	DATE	OFFICE	SURNAME	DATE	OFFICE	SURNAME	DATE

To Vantage Press
you have my permission
to use the quotation from
the Santorian, December 1984,
in the forthcoming book Experiences
in Envi. Szentation.

cc Culhan KMS

17128 s.w. Eldorado
Tigard, Oregon 97224
August 6, 1993

Christine Gebbie
Administrator HIV-AIDS Program
% Office of the President
Whitehouse
Washington D. C./20510

Dear Mrs. Gebbie,

PERMISSION TO QUOTE AN ARTICLE FROM THE "SANITORIAN"

When you were the State Health Officer in Oregon you wrote an article for the "SANITORLAN"-- the news letter for the Oregon Association of Sanitarians. A copy of the article is enclosed.


I am having a book published by VANTAGE PRESS, INC. at 516 West 34th St. New York, NY 10001. The title of the book is "EXPERIENCES IN ENVIRONMENTAL SANITATION". Leonard Zimmerman will be coordinating the publication.

In order to incorporate your message in the book, we need to have written permission.

I am enclosing a stamped , self-addressed envelope for your use-- or you may may your permission to Mr. Zimmerman at VAntage Press.

thank you in advance.

sincerely,


William B. Culham

Congratulations on your recent appointment to your federal office.

The non²professional groups of environmentalists were strong ~~activists~~¹ and their activities were reflected in the direction of health planning. One change was to have ~~management specialists~~² directing the various divisions of health and sanitation. Recognizing this, the Oregon Association of Sanitarians requested the newly¹ appointed administrator of the health division² Mrs. Kristine Gebbie¹ to write a guest editorial ^{they} for the association¹ news letter², the ¹SANITORIAN².
 the December 1984 issue^{of}

Mrs. Gebbie wrote²

^{line #} "Environmental health? A healthy environment?

Environmental ~~Public Health~~? Environmental protection?

Whatever it is called, what is it? Are we effective in it?

By whatever name those engaged in the profession of protecting the public's health through modification or control of the environment have a long and proud record. Many have pointed out the significant gains in life span achieved in the last century are due in large part to food supply, drinking water, waste disposal and housing rather than^F biomedical science advances which fill the news casts. Members of the Oregon Environmental Health Association carry a contemporary responsibility which at times, is difficult to define.

The use of the word "environment" in public health precedes the environmental/ecological movement of the last 20 years having its origin in the triad used to describe

Letter
 E
 v
 e
 n
 t
 s
 d
 i
 s
 e
 a
 s
 e
 t
 r
 a
 n
 s
 m
 i
 s
 s
 i
 o
 n
 :
 a
 g
 e
 n
 t
 ,
 h
 o
 s
 t
 ,
 e
 n
 v
 i
 r
 o
 n
 m
 e
 n
 t
 .
 I
 t
 r
 e
 f
 e
 r
 s
 I
 t
 h
 i
 n
 k
 ,
 n
 o
 t
 j
 u
 s
 t
 t
 o
 w
 a
 t
 e
 r
 ,
 t
 r
 e
 e
 s
 ,
 a
 n
 d
 a
 i
 r
 ,
 b
 u
 t
 t
 o
 a
 n
 y
 p
 o
 r
 t
 i
 o
 n
 o
 f
 t
 h
 e
 p
 h
 y
 s
 i
 c
 a
 l
 o
 r
 s
 o
 c
 i
 a
 l
 s
 y
 s
 t
 e
 m
 i
 n
 w
 h
 i
 c
 h
 a
 n
 a
 g
 e
 n
 t
 o
 r
 d
 i
 s
 e
 a
 s
 e
 o
 r
 i
 n
 j
 u
 r
 y
 c
 a
 n
 a
 f
 f
 e
 c
 t
 a
 s
 u
 s
 c
 e
 p
 t
 i
 b
 l
 e
 h
 o
 s
 t
 o
 r
 v
 i
 c
 t
 i
 m
 .

As technology, life³style and economy have changed over the last 50 years, the ways in which environment can foster or impair the public's health have changed.

Align For example, there is still an ongoing need to assure safe disposal of the byproducts of living, but these include not only human waste, but newly²created chemicals of uncertain toxicity and unknown life span. Food supervision remains critical but surveillance and control must take into account new processing methods and national distribution system and risks of chemical as well as biological con²tamination. Understanding the automobile as an agent and streets and highways as environment is essential to stopping one of our most significant epidemics, that of traffic injuries and deaths. Our collaborators now include not only micro²biologists and chemists but traffic engineers and public safety personnel and sociologists and urban planners.

Many persons were involved in protecting the public health through sanitation and its relationship to the environemnt.

One was Curtiss M. Everts, who served as the Chief Sanitary Engineer of the Sanitary Engineering Section of the State Board of Health from the late 1930's in the to 1960's.



Vantage Press, Inc.

SUBSIDY BOOK PUBLISHERS • 516 W. 34TH ST. • NEW YORK, N.Y. 10001 • TELEPHONE (212) 736-1767 • FAX (212) 736-2273


September 21, 1993

Ms. Kristine M. Gebbie, RN, MN
National AIDS Policy Coordinator
THE WHITE HOUSE
Washington, DC 20500

Dear Ms. Gebbie:

Thank you very much for your letter of September 13th allowing the use of the quotation from the Sanitorian in our forthcoming publication, EXPERIENCES IN ENVIRONMENTAL SANITATION.

Sincerely yours,



LEONARD ZIMMERMAN
Director of Publications

LZ:ca

THE WHITE HOUSE

WASHINGTON

September 14, 1993


Johathan M. Mann, M.D., M.P.H.
Harvard School of Public Health
677 Huntington Avenue
Boston, Massachusetts 02115

Dear Dr. Mann:

Thank you for sharing your concerns about HIV research with me when I was in Boston on August 26th. Both the specific research ideas and your ideas regarding my leadership role were important messages for me to hear.

Please continue sharing both general ideas and specific issues with me as I move along with my new responsibilities. I look forward to seeing you again.

Sincerely,



Kristine M. Gebbie, RN, MN
National AIDS Policy Coordinator

THE WHITE HOUSE
WASHINGTON

September 14, 1993


Dr. Joseph Sodroski
Dana-Farber Cancer Institute
44 Binney Street
Boston, Massachusetts 02115

Dear Dr. Sodroski:

Thank you for sharing your concerns about HIV research with me when I was in Boston on August 26th. Both the specific research ideas and your ideas regarding my leadership role were important messages for me to hear.

Please continue sharing both general ideas and specific issues with me as I move along with my new responsibilities. I look forward to seeing you again.

Sincerely,

A handwritten signature in dark ink, appearing to read "Kristine", with a stylized, flowing script.

Kristine M. Gebbie, RN, MN
National AIDS Policy Coordinator

THE WHITE HOUSE
WASHINGTON

September 14, 1993


Dr. Max Essex
Harvard AIDS Institute
8 Story Street
Cambridge, Massachusetts 02138

Dear Dr. ~~Essex~~ *Max*:

Thank you for arranging my meeting in Boston on August 26th. The level of energy, support and caring in the room were evident. Hearing concerns, goals and experiences from you and your friends and colleagues is essential to my work on behalf of all of us. Please share my thanks with all who made our gathering possible.

Please continue sharing with me as I move along with my new responsibilities. I look forward to seeing you again.

Sincerely,



Kristine M. Gebbie, RN, MN
National AIDS Policy Coordinator

THE WHITE HOUSE
WASHINGTON

September 14, 1993


Dr. Candace Lowe
Harvard AIDS Institute
8 Story Street
Cambridge, Massachusetts 02138

Dear Dr. Lowe:

Thank you for arranging my meeting in Boston on August 26th. The level of energy, support and caring in the room were evident. Hearing concerns, goals and experiences from you and your friends and colleagues is essential to my work on behalf of all of us. Please share my thanks with all who made our gathering possible.

Please continue sharing with me as I move along with my new responsibilities. I look forward to seeing you again.

Sincerely,

A handwritten signature in dark ink, appearing to read "Kristine", with a stylized flourish at the end.

Kristine M. Gebbie, RN, MN
National AIDS Policy Coordinator

KRISTINE M. GEBBIE, R.N., M.N., F.A.A.N.
NATIONAL AIDS POLICY COORDINATOR
DEPARTMENT OF HEALTH & HUMAN SERVICES
Room 729H Humphrey Building
200 Independence Ave., S.W.
Washington, D.C. 20201

DAY Thursday DATE October 14, 1993

TIME 10:30 a.m. LOCATION Room 450 - OEOB

SUBJECT Mandatory Ethics Training

PARTICIPANTS:

THE WHITE HOUSE
WASHINGTON

October 8, 1993

MEMORANDUM FOR ALL NEW APPOINTEES AND EMPLOYEES
WHITE HOUSE OFFICE

FROM: BETH NOLAN *BN*
ASSOCIATE COUNSEL TO THE PRESIDENT

SUBJECT: Mandatory Ethics Training

The mandatory ethics training session for new White House appointees and employees previously changed to take place in the Indian Treaty Room on Thursday, October 14, 1993 at 10:30 a.m., has now been changed back to Room 450 due to a meeting scheduled in the Indian Treaty Room. Stay tuned for further developments.

Please be sure to attend if you have not already been to an ethics briefing.

*Return
did this get on my
calendar?*

THE WHITE HOUSE
WASHINGTON

September 14, 1993

Ms. Harriet Hooper
2876 Rockridge Place
Thousand Oaks, California 91360

Dear Ms. Hooper:


Thank you for writing, and for sharing information about Cancel.

The Food and Drug Administration (FDA) is responsible for the review and approval of any new pharmaceutical products, and you should contact that Agency directly if you have questions regarding this process. The address is:

Dennis Meyers
FDA Executive Secretariat (HF-40)
Parklawn Building, Room 16-70
5600 Fishers Lane
Rockville, Maryland 20857

Best wishes in your efforts.

Sincerely,



Kristine M. Gebbie, RN, MN
National AIDS Policy Coordinator

CC:
FDA Executive Secretariat

THE WHITE HOUSE

WASHINGTON

September 21, 1993

Ms. Harriet Hooper
2876 Rockridge Place
Thousand Oaks, California 91360

Dear Ms. Hooper:

Thank you for writing, and for sharing information about Cancel.

The Food and Drug Administration (FDA) is responsible for the review and approval of any new pharmaceutical products, and you should contact that Agency directly if you have questions regarding this process. The address is:

Dennis Meyers
FDA Executive Secretariat (HF-40)
Parklawn Building, Room 16-70
5600 Fishers Lane
Rockville, Maryland 20857

Best wishes in your efforts.

Sincerely,

Kristine M. Gebbie, RN, MN
National AIDS Policy Coordinator

cc: FDA Executive Secretariat

Prepared by: APO: TFox: 9/21/93:202-690-5560:b:\foxltrs.gbe\hooper.gbe

FILE
COPY

OFFICE	SURNAME	DATE	OFFICE	SURNAME	DATE	OFFICE	SURNAME	DATE

Congratulations on your work with AIDS! 6-30-93

Please consider: CANCEL, a liquid that works on the body's electrical system, made by physicist, Dr. Edward Sopcak of Howell, MI in his lab. --Has proven effective in reversing AIDS to just HIV+ in many cases.

- NO SIDE AFFECTS to humans/animals on well/sick person
- Lowers personal electrical charge, DISSOLVES VIRUS/BUG
- Used successfully on CANCER, AIDS, LUPUS etc.
- Patient should be in charge of their illness, should have options.

Fed Drug assn has formula, still not approved, so cannot be sold. Dr. Sopcak has been making and GIVING AWAY to patients who request this, and whom he feel it could help. Now there is judicial injunction to desist making it even for give away. DRUG ASSN SHOULD APPROVE THIS since even if taken by child or well person there is no side effect. HELP IS NEEDED BY ONE IN AUTHORITY. PLEASE! *more info: NUTRITION HOT LINE; P.O. Box 2245; FARMINGTON, Hills, MI 483-2245*
Ph. 313/684-5529 *Harriet Hooper*

2876 Rockridge Pl.
Thousand Oaks, CA 91360




Wren Building, College of William & Mary

Dr. June Osborn
AIDS COMMISSION
Washington, DC Govt Blds
Washington, D. C.



CLINTON LIBRARY PHOTOCOPY

2876 Rockridge
Thousand Oaks, CA



VIA NEOB
750-17457-

Ms June Osborn
Aids Commission
40 White House
Please forward Washington D.C.

THE WHITE HOUSE
WASHINGTON

September 14, 1993

Ms. Marion Ein Lewin
Director
PEW Health Policy Program Office
Institute of Medicine
National Academy of Sciences
2101 Constitution Avenue
Washington, D.C. 20418

Dear Ms. ~~Lewin~~ *Ein Lewin*:

I recently received the Fall 1993 Newsletter and it's request for "noteworthy items." I wanted to take the opportunity to inform you that on June 25 I was appointed by President Clinton to be the new National AIDS Policy Coordinator.

In developing a strong national policy in response to the HIV epidemic, I will be looking for ways to include all perspectives in our deliberations. I would appreciate hearing from any interested alumni as I take up my new responsibilities.

Sincerely,



Kristine M. Gebbie, RN, MN
National AIDS Policy Coordinator

WASHINGTON

Ms. Marion Ein Lewin
Director
PEW Health Policy Program Office
Institute of Medicine
National Academy of Sciences
2101 Constitution Avenue
Washington, D.C. 20418

I recently received the Fall 1993 Newsletter and it's request for "noteworthy items." I wanted to take the opportunity to inform you that on June 25 I was appointed by President Clinton to be the new National AIDS Policy Coordinator.

Sincerely,

Prepared by: APO: TFox: 9/21/93:202-690-5560:b:\foxltrs.gbe\lewin.gbe

**FILE
COPY**

[illegible]

INSTITUTE OF MEDICINE
NATIONAL ACADEMY OF SCIENCES
2101 CONSTITUTION AVENUE WASHINGTON, D.C. 20418



OFFICE OF HEALTH POLICY
PROGRAMS AND FELLOWSHIPS

September 3, 1993

PHONE: 202/334-1506
FAX: 202/334-1694

CALLING ALL PEW HEALTH POLICY PROGRAM ALUMNI...
Fall 1993 Newsletter

*Send them 2
note on my
Sept. 1*

Call for Career Updates

Plans for the Fall 1993 edition of *Pew Fellows News* are under way. As you know, the newsletter is a useful tool for networking and sharing information but is only as good as the material we receive from you. Please keep us informed about noteworthy items such as awards received and recent career or research accomplishments.

New "Commentary" Column

This edition we are adding a new "commentary" column where we'll pose a question and print some of the more interesting responses. We hope this will prove to be a provocative and stimulating forum in which you'll want to participate. Please limit your response to 250 words or less.

This edition's column will focus on the following scenario:
A critical component of health care reform will be greater reliance on managed care and integrated health care systems. If you were advising the President, what advice would you give him to help assure that managed care is successfully implemented and achieves the desired objectives of improving access to more affordable and appropriate health care services?

Personal Milestones

We will once again accept information for our "On the Lighter Side" column for any personal milestones, such as the birth of children. We will try and include it depending on space availability.

Deadline for Submissions

To meet our publication deadlines, we need to hear from you **no later than Monday, September 27**. You can use the back of this note and return it to my assistant, Karen Orlando. Also, to keep our alumni mailing list as current as possible, please let us know if you have a change of address.

We hope that you've had a good summer and look forward to hearing from you soon. If you have any further questions, please call Karen Orlando at (202) 334-1573.

Sincerely,

Marion Ein Lewin
Director
Pew Health Policy Program Office

THE WHITE HOUSE
WASHINGTON

September 14, 1993


Mr. David Harris
P.O. Box 700
Provincetown, Massachusetts 02657

Dear Mr. Harris:

Thanks for writing. You raise important issues. While I haven't become involved in the immigration policy yet, I am sure I will be before too long. Your personal experiences provide a good illustration of the issues.

My thanks for your interest.

Sincerely,

A handwritten signature in cursive script, appearing to read "Kristine".

Kristine M. Gebbie, RN, MN
National AIDS Policy Coordinator

Mr. David Harris
P.O. Box 700
Provincetown, Massachusetts 02657

Thanks for writing. You raise important issues. While I haven't become involved in the immigration policy yet, I am sure I will be before too long. Your personal experiences provide a good illustration of the issues.

Sincerely,

Prepared by: APO: ALitwinowicz: 9/13/93: 690-5560: b:\harris.913

**FILE
COPY**

[illegible]

Thanks for writing
You raise important issues.
While I haven't become involved in
the immigration ~~issue~~ ^{policy} yet, I will
be before too long. Your personal
experiences provide a good illustration
of the issues.
My thanks for your
interest.
Sincerely,

Withdrawal/Redaction Marker

Clinton Library

DOCUMENT NO. AND TYPE	SUBJECT/TITLE	DATE	RESTRICTION
009. letter	To: Kristine Gebbie; re: Congratulations on Appointment (5 pages)	08/30/1993	b(6)

COLLECTION:

Clinton Presidential Records
National AIDS Policy Office
Kristine Gebbie
OA/Box Number: 3767

FOLDER TITLE:

September Chron Files 1993 [3]

2018-0756-F
jp4790

RESTRICTION CODES

Presidential Records Act - [44 U.S.C. 2204(a)]

- P1 National Security Classified Information [(a)(1) of the PRA]
- P2 Relating to the appointment to Federal office [(a)(2) of the PRA]
- P3 Release would violate a Federal statute [(a)(3) of the PRA]
- P4 Release would disclose trade secrets or confidential commercial or financial information [(a)(4) of the PRA]
- P5 Release would disclose confidential advice between the President and his advisors, or between such advisors [(a)(5) of the PRA]
- P6 Release would constitute a clearly unwarranted invasion of personal privacy [(a)(6) of the PRA]

C. Closed in accordance with restrictions contained in donor's deed of gift.

PRM. Personal record misfile defined in accordance with 44 U.S.C. 2201(3).

RR. Document will be reviewed upon request.

Freedom of Information Act - [5 U.S.C. 552(b)]

- b(1) National security classified information [(b)(1) of the FOIA]
- b(2) Release would disclose internal personnel rules and practices of an agency [(b)(2) of the FOIA]
- b(3) Release would violate a Federal statute [(b)(3) of the FOIA]
- b(4) Release would disclose trade secrets or confidential or financial information [(b)(4) of the FOIA]
- b(6) Release would constitute a clearly unwarranted invasion of personal privacy [(b)(6) of the FOIA]
- b(7) Release would disclose information compiled for law enforcement purposes [(b)(7) of the FOIA]
- b(8) Release would disclose information concerning the regulation of financial institutions [(b)(8) of the FOIA]
- b(9) Release would disclose geological or geophysical information concerning wells [(b)(9) of the FOIA]

Withdrawal/Redaction Marker

Clinton Library

DOCUMENT NO. AND TYPE	SUBJECT/TITLE	DATE	RESTRICTION
010. envelope	To: Kristine Gebbie; [Personal] (Partial) (1 page)	08/30/1993	b(6)

COLLECTION:

Clinton Presidential Records
National AIDS Policy Office
Kristine Gebbie
OA/Box Number: 3767

FOLDER TITLE:

September Chron Files 1993 [3]

2018-0756-F
jp4790

RESTRICTION CODES

Presidential Records Act - [44 U.S.C. 2204(a)]

- P1 National Security Classified Information [(a)(1) of the PRA]
- P2 Relating to the appointment to Federal office [(a)(2) of the PRA]
- P3 Release would violate a Federal statute [(a)(3) of the PRA]
- P4 Release would disclose trade secrets or confidential commercial or financial information [(a)(4) of the PRA]
- P5 Release would disclose confidential advice between the President and his advisors, or between such advisors [(a)(5) of the PRA]
- P6 Release would constitute a clearly unwarranted invasion of personal privacy [(a)(6) of the PRA]

C. Closed in accordance with restrictions contained in donor's deed of gift.

PRM. Personal record misfile defined in accordance with 44 U.S.C. 2201(3).

RR. Document will be reviewed upon request.

Freedom of Information Act - [5 U.S.C. 552(b)]

- b(1) National security classified information [(b)(1) of the FOIA]
- b(2) Release would disclose internal personnel rules and practices of an agency [(b)(2) of the FOIA]
- b(3) Release would violate a Federal statute [(b)(3) of the FOIA]
- b(4) Release would disclose trade secrets or confidential or financial information [(b)(4) of the FOIA]
- b(6) Release would constitute a clearly unwarranted invasion of personal privacy [(b)(6) of the FOIA]
- b(7) Release would disclose information compiled for law enforcement purposes [(b)(7) of the FOIA]
- b(8) Release would disclose information concerning the regulation of financial institutions [(b)(8) of the FOIA]
- b(9) Release would disclose geological or geophysical information concerning wells [(b)(9) of the FOIA]

CLINTON LIBRARY PHOTO COPY

(b)(6)

[010]



Ms. Kristine Gebbie AIDS.
CABINET MEMBER / CZARINA For THE FIGHT
ON AIDS.

C/O THE WHITE HOUSE
1600 PENNS.
WASHINGTON

1600 PENN:WHI 50140309 ** CR 0001
***** AUTOMATED MAIL (MUM) *****
WHITE HOUSE
1600 PENNSYLVANIA AVE NW
WASHINGTON DC 20500-0005



THE ULTIMATE HEALTH CAREER

MIGRANT, HOMELESS, COMMUNITY HEALTH CENTERS

September 14, 1993

Warren "Buck" Buckingham
Special Assistant for Planning & Development
Office of National AIDS Policy
200 Independence Avenue SW
Humphrey Building, Room 738G
Washington, DC 20201



Dear Mr. Buckingham,

This is to formally thank you for serving as Speaker at the 12th Annual Clinical Issues Conference entitled "Teaching in Community Health Centers", sponsored by the National Association of Community Health Centers, Inc. held at the New Orleans Hilton, August 27 - September 1, 1993.

The Clinical Issues Conference will continue to be a major event for NACHC and clinical providers in community and migrant health centers and homeless health projects. Your involvement has been a key part of providing clinicians as administrators and board members with information which promotes clinical excellence and quality care for health centers.

We have not yet completed the analysis of all conference evaluations, however our records show that over 1,600 individuals attended the combined conferences and verbal feedback has been very positive.

Once again, on behalf of the Department of Clinical Affairs of the National Association of Community Health Centers, we wish to thank you for playing an integral role in making the Clinical Issues Conference a tremendous success. Please mark your calendars and plan to join us again next year at the Fountainbleau Hilton Resort in Miami Beach, September 23 - September 28, 1994.

Sincerely,

Darryl Leong, M.D., M.P.H.
Director
Department of Clinical Affairs



NATIONAL ASSOCIATION OF COMMUNITY HEALTH CENTERS

1330 NEW HAMPSHIRE AVENUE, N.W., WASHINGTON, D.C. 20036 (202) 659-8008 FAX (202) 659-8519

THE WHITE HOUSE

WASHINGTON

September 14, 1993


Harvey J. Makadon, M.D.
Beth Israel Hospital
330 Brookline Avenue
Boston, Massachusetts 02215

Dear Dr. Makadon:

Thank you for sharing your concerns about HIV research with me when I was in Boston on August 26th. Both the specific research ideas and your ideas regarding my leadership role were important messages for me to hear.

Please continue sharing both general ideas and specific issues with me as I move along with my new responsibilities. I look forward to seeing you again.

Sincerely,

A handwritten signature in cursive script, appearing to read "Kristine".

Kristine M. Gebbie, RN, MN
National AIDS Policy Coordinator

THE WHITE HOUSE
WASHINGTON

September 14, 1993


J. Davis Allan, M.D.
New England Deaconess Hospital
185 Pilgrim Road
Boston, Massachusetts 02215

Dear Dr. Allan:

Thank you for sharing your concerns about HIV research with me when I was in Boston on August 26th. Both the specific research ideas and your ideas regarding my leadership role were important messages for me to hear.

Please continue sharing both general ideas and specific issues with me as I move along with my new responsibilities. I look forward to seeing you again.

Sincerely,

A handwritten signature in dark ink, appearing to read "Kristine", with a stylized flourish at the end.

Kristine M. Gebbie, RN, MN
National AIDS Policy Coordinator

THE WHITE HOUSE

WASHINGTON

September 14, 1993

Mr. William D. Barcheck
6917 Spur Road
Springfield, Virginia 22153


Dear Mr. Barcheck:

Thank you for taking time to share your views. Clearly you and I see the stamp differently.

This new AIDS Awareness stamp is designed not to honor any individual, but to stimulate all Americans to become fully informed about HIV and AIDS. I am taking this opportunity to ask the National AIDS Hotline to send you some current materials.

I hope they will be informative.

Sincerely,

A handwritten signature in cursive script, appearing to read "Kristine Gebbie".

Kristine M. Gebbie, RN, MN
National AIDS Policy Coordinator

cc: National AIDS Hotline

THE WHITE HOUSE

WASHINGTON

September 14, 1993


Stephen Louis Boswell, M.D.
Infectious Diseases Unit, Gray 5
Massachusetts General Hospital
Fruit Street
Boston, Massachusetts 02114

Dear Dr. Boswell:

Thank you for sharing your concerns about HIV research with me when I was in Boston on August 26th. Both the specific research ideas and your ideas regarding my leadership role were important messages for me to hear.

Please continue sharing both general ideas and specific issues with me as I move along with my new responsibilities. I look forward to seeing you again.

Sincerely,

A handwritten signature in dark ink, appearing to read "Kristine", with a stylized, flowing script.

Kristine M. Gebbie, RN, MN
National AIDS Policy Coordinator